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A prospective cohort study was conducted on eight previously inactive diabetic volunteers (34 – 47 yr) 
with a mean pre-trial HbA1c of 7.45 (±1.34) %, who completed an 8-week endurance exercise 
intervention of moderate intensity (Active Group, AG) as well as two passive controls (age 45-46 yr) 
with a sedentary lifestyle and one active control (AC; age 40yr) who continued with a prior exercise 
programme.  All participants were requested to maintain their usual diet during the exercise intervention.  
The intervention in the AG included a 30-minute cycling program, during which the heart rate fluctuated 
between 60-80 % of age-predicted maximum, repeated three times per week.  The effects of this 
endurance exercise program on signs and symptoms of Diabetic Peripheral Neuropathy (DPN) and 
possible associations between exercise-induced changes in mean resting heart rate (RHR), blood pressure 
(BP), body mass index (BMI), waist circumference, percentage body fat, eight subjective ratings of 
symptoms of pedal discomfort (SRPD), six objective neurological measures of DPN and changes in 
HbA1c, plasma brain- derived neurotrophic factor (BDNF) and adiponectin concentrations were 
determined in all participants (n=11).  The exercise programme resulted in significant improvements 
(p<0.05) in the mean RHR, systolic BP and patellar and ankle reflexes in AG (n=8).  It is concluded that 
the 8-week endurance exercise programme which was not combined with dietary intervention, was not 
successful in improving BMI and abdominal fat indexes, glucose homeostasis and neurological measures 




Six-week old male Spraque-Dawley rats (BW: 276.3± 14.5g) were divided into three groups as Normal 
Control (NC, n=7), Diabetic Control (DBC, n=6) and Exercising Diabetic (DBE; n=7) groups.  Diabetes 
was induced in the animals in DBC and DBE groups by feeding a 10% fructose solution ad libitum for 
first two weeks followed by an intraperitoneal injection of streptozotocin (STZ) (40 mg/kg BW), while 
the animals in NC group were given normal drinking water and injected with vehicle buffer.  One week 
after the STZ injection, animals with 3 h fasting blood glucose (3hFBG) of more than 16 and 12 mmol.L-
1 were considered as diabetic and pre-diabetic, respectively.  After the confirmation of diabetes, a 
progressive 5-week endurance exercise programme (20-22 m/min, 0-4° incline for 60 minutes.day-1) was 
implemented for five days per week in the DBE group and a prediabetic (PDBE) rat, only.  Daily food 
and water intake, weekly 3hFBG and body mass, and post-trial plasma insulin, fructosamine, adiponectin 
and BDNF concentrations were measured in all rats.  Following the exercise programme, elevated 
3hFBG, plasma fructosamine and BDNF concentrations (p>0.05), but hypoinsulinaemia (p<0.05) with 
unchanged plasma adiponectin concentrations (p> 0.05) were recorded in the DBE group (n=6), while 
elevated plasma insulin concentrations was recorded in the PDBE rat with reduced 3hFBG and plasma 
fructosamine and elevated plasma adiponectin and BDNF levels.  Data of this study suggest that 
although endurance exercise when combined with fructose withdrawal, is not effective in reversing STZ-
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1.1 BACKGROUND  
 
Most common of the neuropathies experienced by diabetic individuals is chronic sensorimotor distal 
symmetric polyneuropathy, more simply known as diabetic peripheral neuropathy (DPN).  DPN is 
defined as “the presence of symptoms and/or signs of peripheral nerve dysfunction in individuals with 
diabetes after the exclusion of other causes.” It is a great cause for concern as it can lead to other serious 
complications such as pedal ulcers and possible gangrene and amputation (American Diabetes 
Association (ADA), 2012).  Although there is much evidence confirming the beneficial effects of 
different exercise modalities on glucose control in the Type 2 diabetic patient (Boulton et al., 2005), only 
one research report focusing on the benefits of exercise on DPN has been completed to date (Gurney, 
2011). Gurney (2011) was the first to demonstrate quantifiable changes in sensory function as a result of a 
low-impact balance and strength training intervention in diabetic participants with DPN.   
 
Exercise has been considered a cornerstone of diabetes management, along with diet and pharmacological 
intervention (Sigal et al., 2006).  It is recommended that an accumulation of >30 minutes of moderate 
intensity activity on most days of the week or at least 150 minutes per week of moderate-intensity aerobic 
exercise, or resistance exercise 3 times a week has the most beneficial in managing diabetes (Sigal et al., 
2006; ADA, 2012).  However accumulating evidence suggests that interval training has a greater effect on 
many of the cellular mechanisms (Haram et al., 2009).  It has been successfully used in younger and older 
patients who are in a higher risk category and has been shown to offer greater benefits compared to the 
traditional aerobic exercise interventions (Earnest, 2008). 
 
The beneficial effects of exercise are attributed to an exercise associated decrease in the regulation of 
blood glucose concentration as reflected by the glycosylated haemoglobin concentration (HbA1c) 
resulting from improved glucose uptake (Earnest et al., 2008). Glucose transporter isoform 4 (GLUT4) is 
a key signaling protein which is involved in glucose uptake and removal from the circulation and is a key 
regulator of whole-body glucose homeostasis (Huang and Czech, 2007).  It is important in insulin-
regulated glucose transport and is found in adipose tissues, skeletal and cardiac muscle. Earnest et al. 
(2008) proposed that GLUT4 protein expression increases with regular endurance exercise and that 
impairment in GLUT4 transport/ translocation may be the cause of insulin resistance and impaired 






The resultant increase in HbA1c has been associated with a higher risk of developing retinopathy, 
nephropathy, cardiovascular disease and/or damage to nervous tissue or neuropathy (Topiwala, 2012).  
Endurance, resistance and a combination of both exercise modalities have been associated with a similar 
reduction in HbA1c (Umpierre et al., 2011), but little evidence exists of an association between physical 
exercise and sensory neuropathy (Gurney, 2011). 
 
In 2007 Cuppinin published one of the first papers reporting an exercise-induced elevation blood BDNF 
concentrations attributed to the additional release of BDNF by contracting skeletal muscle. The beneficial 
effects of elevations in brain derived neurtophic factor (BDNF) are well described (Nakagawa et al., 
2000; Cuppinin et al., 2007; Krabbe et al., 2007).  These include i) effective lowering of blood glucose 
concentration by enhancing the glucose uptake by skeletal muscle, ii) enhanced sensitivity of insulin and 
iii) increased thermogenic activity and resting metabolic rate (Nakawaga et al., 2000).   
 
As Type 2 Diabetes Mellitus (T2DM) is characterized by both diminished insulin sensitivity and deficient 
insulin secretion, measuring insulin concentration alone in fasting plasma samples is also very 
informative.  While it alerts the physician to possible reasons for the hypoglycaemia common in Type 1 
diabetic patients, it provides feedback regarding the body's sensitivity to insulin in T2DM patients. Even 
with normal blood glucose concentrations, hyperinsulinaemia may indicate that the pancreas is working 
harder than normal to reduce the blood glucose concentrations and the presence of greater resistance to 
insulin's effect, a condition known as "insulin resistance syndrome".  
 
Adiponectin has been reported to play an important role in the modulation of carbohydrate and lipid 
metabolism in insulin-sensitive tissues. Decreased circulating adiponectin levels have been reported by 
Yamauchi et al. (2001) in genetic and diet-induced murine models of obesity and by Arita et al. (1999) in 
diet-induced obesity in humans. Low levels of adiponectin have also been reported in the development of 
insulin-resistance in both obese and lipoatrophy mouse models (Yamauchi et al., 2001). In human studies 
it has been reportedly shown that plasma levels of adiponectin are significantly lower in insulin resistant 
state of T2DM and that adiponectin is a major modulator of insulin action (Weyer et al., 2001). 
 
There is currently only one publication that explores the effects of exercise on DPN (Gurney, 2011). The 
possible associations between effects of exercise on DPN and between exercise-induced changes in DPN 
and exercise-induced changes in both HbA1c, adiponectin and BDNF levels are thus an open area for 
future investigation.   
 
Due to the difficulties experienced in obtaining compliance from a large number of human participants 
and controlling the large number of variables that could affect the results, a laboratory study on rodents, 
in which (i) diabetes was induced using a combination of fructose supplementation and a streptozotocin 










To determine the effects, of an 8-week endurance exercise programme on peripheral sensory neuropathy 
in T2DM patients and the possible association of these signs and symptoms with quantitative measures of 
glucose control and change in the concentration of BDNF and adiponectin in blood.  
 
Part Two 
To determine the effects of  a 5-week exercise programme, in combination with withdrawal of fructose 
supplementation, on blood insulin, fructosamine, BDNF and adiponectin concentrations and possible 





 To determine the effects of an 8-week endurance exercise program on signs and symptoms of 
peripheral sensory neuropathy in T2DM patients 
 To establish whether an 8-week program of regular endurance exercise which is not accompanied 
by a change in dietary intake, results in a significant effect on HbA1c and blood BDNF and 
adiponectin in T2DM patients with DPN  
 
Part Two 
 To determine the effects of fructose withdrawal, together with a 5-week exercise program in pre-
diabetic and diabetic rats on glucose control as reflected by systemic concentrations of  
fructosamine, insulin, BDNF and adiponectin  
 To establish the possible relationships between the various systemic measures of glucose control 








As only one scientific experimental work has been published on the effects of exercise on DPN and the 
prior published evidence of an increase in BDNF concentrations and better controlled HbA1c following 
endurance exercise training, is not conclusive, the following  null hypotheses were set: 
 
 Regular endurance exercise does not improve DPN  
 Regular endurance exercise alone does not reduce  HbA1c in T2DM participants with DPN 
 The attenuation of HbA1c is not related to exercise–induced changes in blood BDNF 
concentrations 
 Resting blood BDNF and adiponectin concentrations do not change following an 8-week 
program of regular endurance 
 
Part Two 
As no study has yet been performed on the effect of exercise training on rats in which diabetes has been 
induced using the Fructose+ 40 mg STZ /kg model (Islam and Du Toit, 2009), the following null 
hypotheses were set: 
 
 Regular endurance exercise in combination with fructose withdrawal,  will not improve glucose 
control as reflected by circulating  fructosamine, insulin, BDNF  and adiponectin  concentrations 





















REVIEW OF THE RELATED LITERATURE 
 
2.1 An Introduction to Diabetes Mellitus 
 
Diabetes Mellitus (DM) is a chronic multifaceted metabolic condition characterised by consistent 
hyperglycaemia which manifests in humans with a fasting blood glucose >7 mmol.l-1 or 126 mg.dL-1 and 
an HbA1c > 6.5% (ADA, 2005).  As insulin is the hormone that is primarily responsible for glucose 
uptake into myocytes under normal conditions, the hyperglycaemia is caused by insulin insensitivity 
and/or the decreased production of insulin by the pancreas (ADA, 2005; Desphande et al., 2008; Mayo 
Clinic, 2014).  
  
Depending on the aetiology, DM is categorised as either Type 1 (T1DM) or Type 2 (T2DM).  T1DM is 
typically occurs at a young age and is a condition that involves pancreatic β-cell destruction leading to 
absolute insulin deficiency (ADA, 2005; Desphande et al., 2008).  T2DM, which, according to the most 
recent report of the WHO (WHO, 2014), currently accounts for 90–95% of those with DM, ranges from 
predominant insulin resistance with relative insulin deficiency in early stages, to a predominant insulin 
secretory defect with insulin resistance in more prolonged or severe cases (ADA, 2005, WHO, 2014).  
 
2.2 Insulin Secretion and Glucose Uptake  
 
Glucose metabolism is the process in which the body converts carbohydrate in food that is consumed, 
into glucose and used as an energy source for the body (Ogunjimi, 2013).  The uptake of glucose into 
cells is aided by insulin that is exclusively produced by β-cells which are located within the Islets of 
Langerhans of the pancreas.  In the protein assembly of insulin, the messenger RNA transcript is 
translated into an inactive protein called preproinsulin.  Preproinsulin contains an amino-terminal signal 
sequence that is needed in order for the precursor hormone to pass through the membrane of the 
endoplasmic reticulum (ER).  Upon entering the ER, the preproinsulin signal sequence is proteolytically 
removed to form proinsulin.  The end product of the biosynthesis is a mature and active insulin.  Finally 
the insulin is packaged and stored in secretory granules, which accumulate in the cytoplasm, until its 
release is triggered (Cartailler, 2014). 
 
As is shown in Figure 2.1, the process by which insulin is released from the β-cells in response to changes 
in blood glucose concentration, is a mechanism involving Type 2 glucose transporters (GLUT2) that 
mediate the entry of glucose into the β-cells.  This glucose is phosphorylated by the enzyme glucokinase.  





adenosine tri-phosphate (ATP), the energy molecule.  The increased ATP:ADP ratio causes the ATP-
gated potassium (K+) channels in the cellular membrane to close, preventing K+ from being shunted 
across the cell membrane.  The subsequent rise in positive charge inside the cell due to the increased 
concentration of K+, leads to the depolarization of the cell.  The net effect is the activation of the voltage-
gated calcium channels which results in the abrupt increase in intracellular calcium concentrations and 
triggers activation of the insulin-storing granules and the release of insulin from the β-cells and its 





















Figure 2.1: The mechanism of insulin secretion from the β pancreatic cells (Adapted from Cartailler, 
2014) 
 
Insulin molecules circulate throughout the blood stream until they bind to their associated insulin 
receptors.  The insulin receptors promote the uptake of glucose into tissues that contain type 4 glucose 
transporters (GLUT4), such as the skeletal muscles and fat.  The initial binding of insulin to its receptor 
initiates a signal transduction cascade that results in the removal of glucose from blood plasma (Figure 
2.2).  These changes can last from minutes to hours (Cartailler, 2014).  
 





The body's response to blood glucose therefore requires the coordination of an array of mechanisms.  
Failure of any one component involved in insulin regulation, secretion, uptake or breakdown can lead to 
abnormally high levels of blood glucose resulting in DM (Cartailler, 2014). 
 
2.3 Lipid Metabolism 
 
The inability of the body to produce and/or utilize insulin can also affect the metabolism of lipids 
(Ogunjimi, 2013).  From the findings of Boden et al. (2002) it is now clear that elevation of plasma free 
fatty acids (FFAs) plays an important role in the development of T2DM by causing insulin resistance.  
Adipocytes take up and store FFAs and during periods of low energy intake the body uses its fat reserves 
i.e. FFAs being released for other tissues to be used as fuel.  However, if plasma FFA levels are elevated 
for more than a few hours, they will cause insulin resistance (Boden et al., 2002).  
 
The mechanisms by which elevated FFA levels result in insulin resistance have been determined in 
human skeletal muscle, where most insulin-stimulated glucose uptake, glucose transport or 
phosphorylation occurs.  It has been suggested that it is not the accumulation of fat in muscle cells that 
causes insulin resistance, but rather the accumulation of other metabolites, including diacylglycerol, that 
occur (Boden et al., 2002). It has also been proposed that FFAs can cause insulin resistance by increasing 
oxidative stress (Ceriello, 2000).  Reactive oxygen species have been shown to activate protein kinase C 
(PKC) and the nuclear factor β (NF-β) pathway, thereby contributing to insulin resistance (Ceriello, 
2000).  Thirdly, FFAs also affect the functioning of insulin in the liver and thus contribute to hepatic 
overproduction of glucose and to elevated circulating blood glucose levels (Ceriello, 2000). 
 
An increase in visceral fat is however believed to cause insulin resistance by mechanisms that do not 
directly involve FFAs.  Adipose tissue is a source of inflammatory adipokines, which also act as 
mediators, such as tumor necrosis factor (TNF), interleukin (IL)-6 and peptides that include resistin, 
leptin and adiponectin (Boden and Laakso, 2004).  
 
Of the above-mentioned adipokines, adiponectin is most likely to affect insulin sensitivity.  Produced 
exclusively in adipocytes, it stimulates FFA oxidation, decreases plasma triglycerides, and improves 
glucose metabolism by increasing insulin sensitivity (Weyer et al., 2001).  The plasma levels of 
adiponectin in Caucasians and Pima Indians are negatively correlated with % body fat and plasma insulin 
levels and are positively correlated with insulin-mediated glucose uptake (Weyer et al., 2001).  In 
addition, plasma levels of adiponectin are lower in individuals with T2DM than in age and body mass 
matched individuals without DM.  Thus the impaired release of adiponectin that occurs in obesity is 
thought to also contribute to insulin resistance and development of T2DM although the mechanism 






2.4 Protein Metabolism 
 
Insulin is also responsible for the development of new proteins, transporting amino acids into cells and 
guarding against the breakdown of proteins (Ogunjimi, 2013).  Pereira et al., (2008) demonstrated that 
T2DM men have insulin resistance of protein metabolism.  The study further showed that insulin 
resistance may result in inhibition of modest stimulation of protein synthesis that occurs following insulin 
and amino acid infusion.  Studies by Stump et al. (2003) and Asmann et al. (2006) showed impaired 
insulin-stimulated glucose disposal, muscle mitochondrial ATP production, and a reduction in 
mitochondrial protein synthesis in T2DM patients.  
 
These findings are important as they indicate that T2DM involves defective protein metabolism and that 
the finding of impaired insulin plus amino acid stimulated protein synthesis in T2DM men may be of 
clinical importance (Pereira et al., 2008). 
 
2.5 Signs and Symptoms of DM 
 
The increased blood glucose levels affecting fat, carbohydrate and protein metabolism lead to symptoms 
that are associated with DM.  These typically include polyuria, polydipsia, weight loss, polyphagia, 
blurred vision and impairment of growth and susceptibility to certain infections (ADA, 2005; Guyton and 
Hall, 2011).  
 
When blood glucose concentrations rise and pass the 'renal threshold' (between 180 and 220 mg.dL-1), the 
kidneys excrete the glucose with the urine. This causes an osmotic shift of extra water into the urine from 
the blood, leading to polyuria.  The resulting dehydration causes excessive thirst or polydipsia (ADA, 
2005; Guyton and Hall, 2011).   
 
Increased appetite or polyphagia and a loss of body mass has been reported to occur when glucose from 
the blood cannot enter the tissue cells resulting in starvation of the tissues and increased hunger.  
Insufficient insulin reduces the diffusion of glucose into tissue cells and its’ use as glycolytic substrate.  
When this occurs, the body starts burning fat and muscle for energy, causing a reduction in overall body 
weight (ADA, 2005; Guyton and Hall, 2011).  
 
Blurred vision can also be attributed to the high blood glucose concentrations.  During the initial stages of 
retinopathy, the damage is limited to micro aneurysms in the blood vessel walls. This occurs as a result of 
the conversion of glucose to sorbitol during the intracellular polyol pathway, which increases the osmotic 
stress.  Although these can leak blood and fluid, they do not usually affect vision unless there is oedema 
in the macula.  At more advanced stages, there is blockage of the blood vessels that supply the retina 





However, these are weak and result in hemorrhages, which can cause blurred and patchy vision.  Over 
time, this bleeding leads to scar tissue formation, which can result in retinal detachment, and if untreated, 
blindness (NHS, 2014). 
 
DM also leads to poor blood circulation due to increased predisposition to atherosclerosis and 
arteriosclerosis. Creager et al. (2003) explains that in normal endothelial cells, biologically active 
vasodilatory substances are synthesized and released. This facilitates adequate blood flow and nutrient 
delivery while preventing thrombosis and leukocyte diapedesis.  Among the important molecules 
synthesized by the endothelial cell is nitric oxide (NO).  The bioavailability of NO represents a key 
marker in vascular health as it causes vasodilation of vascular smooth muscle cells and protects the blood 
vessel from endogenous injury (atherosclerosis) by preventing platelet and leukocyte interaction with the 
vascular wall and inhibit vascular smooth muscle cell proliferation and migration.  Therefore the loss of 
endothelium-derived NO allows increased activity of proinflammatory transcription factor nuclear factor 
kappa β (NF-κβ), resulting in expression of leukocyte adhesion molecules and production of chemokines 
and cytokines.  This promotes monocyte and vascular smooth muscle cell migration into the intima and 
formation of macrophage foam cells, characterizing the initial stages of atherosclerosis. Endothelium-
dependent vasodilation is therefore abnormal in patients with T1DM and T2DM and the body’s ability to 
repair tissue and heal wounds is affected.  This can result in wounds remaining open and unhealed for 
months, increasing the risk of fungal and bacterial infections and even gangrene in patients with DM 
(Guyton and Hall, 2011).  
 
Although T2DM remains a leading cause of cardiovascular disorders, blindness, end stage renal failure 
(ADA, 2005), a further complaint amongst diabetic patients is the development of chronic sensorimotor 
distal symmetric polyneuropathy.  It is the most common of the neuropathies, more simply known as 
diabetic peripheral neuropathy (DPN) and has been defined as “the presence of symptoms and/or signs of 
peripheral nerve dysfunction in people with DM after the exclusion of other causes” (Boulton et al., 
2005).    
  
2.6 Pathogenesis of DM and DPN 
 
T2DM 
In early disease stages of the T2DM patient, insulin production is normal or increased in absolute terms, 
but the insulin sensitivity is usually reduced.  In most patients with T2DM, especially the obese, insulin 
resistance in target tissues (liver, muscle, adipose tissue and the myocardium) is a prominent feature.  
This results in both glucose overproduction and underutilization (ADA, 2012).  Abnormal Islet cell 
function is a key and essential factor of T2DM.  In addition, pancreatic -cells of the patient with chronic 






The factors that lead to the development of diabetic neuropathy are not completely understood and a few 
biochemical mechanisms will be discussed.  
 
 
Figure 2.3: General Overview of Diabetic Neuropathy (Adapted from Duby et al., 2004; AGEs Advanced 
Glycation End products, RAGE Receptor of Advanced Glycation End products, ROS Reactive Oxygen Species, 
TCA Tricarboxylic Acid Cycle, NADH Nicotinamide Adenine Dinucleotide)  
 
As is shown in Figure 2.3, DM promotes elevated intracellular concentrations of glucose that can take 
part in a number of different pathological processes.  Glucose can react with ROS to form carbonyls that 
can react with proteins or lipids to produce glycoxidation or lipoxidation compounds, respectively.  
Glucose and its metabolites can also create carbonyl complexes with proteins, producing AGEs that 
contribute to oxidative stress.  Alternatively, glucose metabolism itself creates free-radicals during normal 
production of ATP.  The presence of excessive glucose may lead to increased production of reducing 
agents (i.e. NADH and FADH2) through glycolysis and the Tricarboxylic acid cycle.  The excess of 
electron donors may result in a dangerous imbalance in the mitochondrial electron transport chain that 
could accelerate the production of superoxide, a highly reactive free radical (Lin, 2012).  Superoxide 
anions are capable of intense tissue damage and may contribute to the activation of PKC (a superfamily of 
12 isoenzymes that act in the transduction of intracellular signalling and are activated by phosphorylation 
and subsequent binding to the second messenger diacylglycerol).  Glucose and other sugars can also 





which can further degrade or react to produce AGEs.  This process occurs in euglycaemic individuals and 
normally affects only longer-lived proteins, but hyperglycaemia provides an excess of substrate i.e. 
glucose that may accelerate the reaction.  The glycation of essential proteins could alter their structure and 
impair their function (Lin, 2012).   
 
Receptors for AGEs have also been identified as contributors to oxidative stress and activate signal-
transduction pathways, such as PKC and mitogen-activated protein.  The polyol pathway can induce and 
drive secondary metabolic processes that promote intracellular instability and decay.  It is an alternative 
catabolic pathway that is activated by elevated intracellular glucose levels.  The first redox reaction of the 
polyol pathway couples the reduction of glucose by the enzyme al-dose reductase with the oxidation of 
NADPH to NADP+, producing sorbitol.  Sorbitol is further oxidized to fructose by sorbitol 
dehydrogenase, which is coupled with the reduction of NAD+ to NADH.  A high rate of "flux" of glucose 
through the polyol pathway has been hypothesized to be pathogenic, primarily by increasing the turnover 
of cofactors NADPH and NAD+ (Duby et al., 2004; Lin, 2012).  The reduction and regeneration of 
glutathione require NADPH, and depletion of glutathione could contribute to oxidative stress and the 
accumulation of toxic species.  An imbalance in the NADH: NAD+ ratio could also result in increased 
production of AGEs and the activation of diacylglycerol and PKC.  There is mounting evidence that PKC 
may therefore be a critical conductor in the metabolic pathologies associated with diabetic neuropathy 
(Duby et al., 2004; Lin, 2012).  
 
Other causes may be altered gene expression with altered cellular phenotypes, changes in cell physiology 
relating to endoskeletal structure or cellular transport, or reduction in neurotrophins e.g. Brain Derived 
Neurotropic factor (BDNF) (Lin, 2012).  
 
2.7 Risk factors for DM 
 
Fixed risk factors 
Certain racial/ethnic groups have increased risk of developing DM.  Greater insulin resistance has been 
shown in the Latino population and more β-cell dysfunction has been seen in East Asians (Inzucchi et al., 




Pederson (2009) explains that physical inactivity leads to the accumulation of visceral fat. This visceral 
fat acts as an endocrine gland subsequently activating a network of inflammatory pathways resulting in 
chronic systemic inflammation which in turn is associated conditions including T2DM, cardiovascular 






Physical inactivity may induce negative effects on relatively fast-acting cellular processes in skeletal 
muscles or other tissues, elevating harmful plasma concentrations of triglycerides and lowering serum 
high density lipoprotein cholesterol (HDL) concentrations.  Even prolonged sitting time is a high-risk 
factor for diseases like coronary artery disease or glucose metabolism in those with T2DM.  As sitting for 
prolonged periods results in reduced cumulative energy expenditure it may have chronic effects on the 
predisposition to become overweight (Owen et al., 2009).  
 
Increased BMI/ Central Obesity 
BMI is calculated by dividing mass (kg) by height (m) square. In Table 2.1 values for each class of 
obesity and the relative risk of comorbidities and Figure 2.4 shows relative risk of mortality, cardiac heart 
disease and T2DM to BMI.  
 
Table 2.1: Body Mass Index and risk of co-morbidities (Adapted from WHO, 2000) 
 
 BMI (kg.m-2) Risk of Comorbidities 
Healthy weight 
Overweight 
Obese Class I 
Obese Class II 
Obese Class III 
18.5 – 24.9 
25.0 – 29.9 
30.0 – 34.9 




























Figure 2.4: Relative risk of mortality, coronary heart disease (CHD) and T2DM according to body mass 
index (BMI) (Adapted from Manson et al., 1995).  
 
There is however evidence that intra-abdominal (visceral) obesity is the most dangerous obesity 
phenotype and that waist circumference is better than BMI to predict cardiometabolic risk (International 
Chair on Cardiometabolic Risk, 2013). Central obesity is defined as waist circumference ≥ 94cm for 
Caucasian men and ≥ 80cm for Caucasian women and for Asian men ≥ 90cm and for Asian women ≥ 





International DM Federation (IDF) in 2005 as a prerequisite for the diagnosis of metabolic syndrome 
(MetS) in addition to any two of the following risk factors listed below (Alberti et al., 2005).  
 
MetS also known as insulin resistance syndrome, is a cluster of three or more of the following common 
co-morbidities; 
 Fasting plasma glucose concentration ≥ 6.1mmol.l-1 
 Serum triglyceride concentration ≥ 1.69mmol.l-1 
 HDL concentration < 1.04mmol.l-1 
 Blood pressure ≥ 130/85 mmHg or controlled with medication 
 Waist circumference of > 88cm in women and 102cm in men 
 
Metabolic studies have shown that among equally obese patients, subjects with an excess of intra-
abdominal adipose tissue have the worst metabolic risk profile.  These participants show insulin 
resistance and compensatory hyperinsulinaemia as an indication of insulin resistance.  The presence of 
visceral obesity and insulin resistance have been associated with dyslipidaemic profile that includes 
hypertriglyceridaemia, low HDL cholesterol concentration, elevated apolipoprotein B as a marker of an 
increased concentration of atherogenic lipoproteins, and an increased concentration of small, dense LDL 
particles.  In addition to the dyslipidaemic insulin resistant profile, these individuals present with 
impaired fibrinolysis, an increased susceptibility to thrombosis, endothelial dysfunction and an 
inflammatory profile (Lemieux et al., 2000; Després and Lemieux, 2000).  
 
A close relationship between visceral obesity and elevated C-reactive protein (CRP) levels has also been 
reported (International Chair on Cardiometabolic Risk, 2013).  This could be due to macrophage 
infiltration of the adipose tissue of abdominally obese patients.  These macrophages can produce 
inflammatory cytokines such as TNF-α and IL-6, which can have a local impact on adipose tissue 
metabolism as well as systemic effects.  This can exacerbate the dysmetabolic profile seen among patients 
with an excess of intra-abdominal adipose tissue.  For instance, the TNF-α could make adipose tissue 
insulin resistant, and it also has an inhibitory effect on the production of adiponectin (an important 
adipose tissue-derived cytokine that has been suggested to have anti-artherogenic and anti-diabetic 
properties).  In addition, the release of IL-6 by fat cells is known to stimulate the production of CRP 
through the liver (International Chair on Cardiometabolic Risk, 2013). 
 
The hyperlipolytic state and pro-inflammatory profile of intra-abdominal obesity could therefore explain 
the collection of metabolic abnormalities found in intra-abdominally obese patients (International Chair 









When the human body is under threat it elicits a number of neuroendocrine responses.  These include an 
increased secretion of catecholamines from the adrenal gland and the activation of the sympathetic 
nervous system.  Tsatsoulis and Fountoulakis (2006) describe how stress allows for a “fight or flight” 
response to occur by mobilizing endogenous substrate and inducing a state of insulin resistance in the 
liver and skeletal muscles.  The release of the stress hormone, cortisol, also increases glucose in the 
bloodstream, in an enhancement of gluconeogenic processors (Tsatsoulis and Fountoulakis, 2006). 
 
2.8 Diagnostic Laboratory Tests 
 
2.8.1 Fasting Blood Glucose (FBG) 
FBG measures blood glucose after an 8 hour fast (preferably done 1st thing in the morning after an 
overnight fast).  This is often the first test done to diagnose DM (WebMD, 2012).  
Interpretation of the results of a fasting test with respect to glucose levels in the human body are as 
follows (Diabetes.co.uk, 2014): 
 Normal: 3.9 to 5.5 mmol.l-1 (70 to 100 mg.dl-1) 
 Pre-diabetes or Impaired Glucose Tolerance: 5.6 to 7.0 mmol.l-1 (101 to 126 mg.dl-1) 
 Diagnosis of DM: more than 7.0 mmol.l-1 (126 mg.dl-1) 
 
2.8.2 2 hour Postprandial Blood Glucose  
This measures the blood glucose exactly 2 hours after the start of eating a meal.  This test is not used in 
the diagnosis of DM, but rather in understanding the effects of food choices of blood glucose.  Ideally it is 
recommended that values remain less than 7.8mmol.l-1 for people 50 years or younger, less than 
8.3mmol.l-1 for persons aged 50-60 years and less than 8.9 mmol.l-1 in persons older than 60 (WebMD, 
2012).  
 
2.8.3 Random Blood Glucose (RBG) 
This is the measurement of blood glucose at any time of the day regardless of what was ingested.  This is 
not used to diagnose DM (WebMD, 2012).  A level of 11.1 mmol.l-1 or more in the blood sample 
indicates DM (Diabetes.co.uk, 2014). 
 
2.8.4 Oral Glucose Tolerance Test (OGTT) 
This is considered the gold standard test to be carried out for the diagnosis of DM.  It involves drinking a 
sugar solution (i.e. water with 75g of sugar added) after an 8 hour fast.  The blood glucose concentrations 






Impaired glucose tolerance (IGT) is diagnosed when the fasting plasma glucose is less than 7 mmol.l-1 
and the two hour glucose level is between 7.8 and 11 mmol.l-1.  This is also commonly referred to as "pre-
diabetes" as IGT is associated with a higher risk of developing DM (MedicineNet.com, 2014). DM is 
diagnosed when two diagnostic tests done on different days show that the blood glucose concentrations 
are either the two hour level is greater than 11.1 mmol.l-1 or the fasting glucose is noted as greater than 7 




HbA1c is a laboratory blood test that represents the average level of blood glucose over the previous 3 
months (Topiwala, 2012).  It is linearly related to the average blood glucose over the past 1-3 months (but 
it is somewhat weighted to the past 2-4 weeks) (MDRTC, 2013).  It ranges from less than 5.7% in non-
diabetic individuals, to 5.7% -6.4% in the pre-diabetic population and > 6.5% in patients with DM 
(Topiwala, 2012).  An increase in HbA1c above 6.5% has been associated with a higher risk of 
developing retinopathy, nephropathy, cardiovascular disease (CVD) and/or damage to nervous tissue or 
neuropathy (Topiwala, 2012). 
 
2.9 Other relevant systemic biochemical measures 
 
2.9.1 Plasma Fructosamine  
Fructosamine is a glycosylated protein formed when carbohydrate and protein, primarily albumin, bond 
non-enzymatically.  It can be used as an assessment for glycaemic control and has been shown to be 
proportional to blood glucose over a longer period (half-life about 17 days in the circulation).  
Fructosamine therefore represents a shorter term glycaemic control than HbA1c (Rigg, 2012), but may be 
preferred in rodents or humans with hemoglobin variants or altered red blood cell lifespans that can skew 
HbA1c readings (College of American Pathologists, 2010). 
 
2.9.2 Insulin Concentration/ HOMA IR/ Insulingenic index 
T2DM is characterized by both diminished insulin sensitivity and deficient insulin secretion. Insulin 
sensitivity can be measured by the hyperinsulinaemic-eugyclycaemic ‘clamp’ or the insulin response to 
an intravenous glucose infusion and, although labour intensive, these are often considered the "gold 
standards" for assessing insulin sensitivity and secretion (Bonora et al., 2002).  
  
The Homeostasis Model Assessment (HOMA) is commonly used to estimate the steady state of β cell 
function and insulin sensitivity as percentages in humans.  The degree of insulin resistance is estimated at 
the baseline by computing an insulin resistance score (HOMA IR) using the following formula:  
                      HOMAIR = fasting plasma glucose (mmol.l-1) x fasting serum insulin (mU/l) 





Low HOMA IR values indicate high insulin sensitivity, whereas high HOMA IR values indicate low 
insulin sensitivity (insulin resistance) (Bonora et al., 2002)  
 
The corrected insulin response (CIR) however appears to be the most useful index in humans, particularly 
when measured in the 30-minute post load sample (Hanson et al., 2000).  CIR is a measure of 
postprandial insulin secretion, but can be only calculated using the following formula for time points after 
the oral glucose load has been administered. 
 
Measuring insulin concentration alone in fasting plasma samples is however according to Hanson et al. 
(2000) also very informative.  While it alerts the physician to possible reasons for the hypoglycaemia 
common in T1DM patients, it provides feedback regarding the body's sensitivity to insulin in T2DM 
patients.  Even with normal blood glucose concentrations, hyperinsulinaemia may indicate that the 
pancreas is working harder than normal to reduce the blood glucose concentrations and the presence of 
greater resistance to insulin's effect, a condition known as "insulin resistance syndrome."   
Normal fasting insulin concentrations in human plasma lie within the range of 5- 20 mcU.mL-1 (micro 
unit per milliliter), while normal concentrations in rodents are 0.5-10ng.ml1 (Hanson et al., 2000).  In 
addition to the aforementioned increased insulin resistance syndrome which is characteristic of T2DM 
and associated central obesity, an abnormally high concentration may indicate ingestion of an excessive 
amount of insulin or sulfonylurea-induced hypoglycaemia. 
An ultra-sensitive insulin Enzyme Linked Immunosorbent Assay (ELISA) is a common method for the 
evaluation for the quantitative determination of insulin concentrations in plasma.  The solid phase two site 
enzyme immunoassay is based on direct sandwich technique in which two monoclonal antibodies are 
directed against separate antigenic determinants on the insulin molecule.  During incubation insulin in the 
sample reacts with perioxidase-conjugated anti-insulin antibodies and anti-insulin antibodies bound to the 
microtitration well.  A simple washing step removes unbound enzyme labelled antibody. The bound 
conjugate is detected by reaction with 3,3’, 5,5’– tetramethylbenzidine.  The reaction is stopped by adding 






2.9.3 Plasma Adiponectin 
Researchers have shown that adipose tissue is not merely an inert storage depot for lipids, but is an 
important endocrine gland that plays a role in endocrine, metabolic and inflammatory signals for the 
control of energy homeostasis.  The proteins released are known as adipocytokines which include leptin, 
tumor necrosis factor (TNF)-alpha(α), plasminogen activator inhibitor type 1 (PAI-1), adipsin, resistin 
and adiponectin (Maju, 2003).  
 
Adiponectin is an important collagen-like protein that is synthesized in and secreted from differentiating 
white adipose tissue and circulates in high concentrations in the serum (Maju, 2003).  Although it has 
anti-inflammatory properties that include suppression of macrophage phagocytosis, TNF-α secretion and 
blockage of monocyte adhesion to endothelial cells (Maju, 2003), adiponectin also plays an important 
role in the modulation of carbohydrate and lipid metabolism in insulin-sensitive tissues and may be 
critically important in high-risk cohorts, in whom augmentation of the anti-inflammatory and antidiabetic 
properties is required (Simpson and Sing, 2008).  
 
In addition to significant inhibitory effects on TNF-α–induced monocyte adhesion and adhesion molecule 
expression, suggesting an increased risk of adverse health effects at serum concentrations below plasma 
levels of 5–25 μg/ml (Ouchi et al., 1999), it has paradoxically been reported to be of lower concentration 
in obese individuals (Arita et al., 1999).  Kappes and Loffler (2000) attribute this to the development of a 
negative feedback mechanism which regulates the expression of adiponectin in obese persons. While low 
levels of adiponectin in obese individuals have also been related to the development of insulin-resistance 
in obese mouse models (Yamauchi et al., 2001), it has been shown that plasma levels of adiponectin are 
significantly lower in insulin resistant states of T2DM and a major modulator of insulin action in humans 
(Weyer et al., 2001).  Infusing recombinant full-length adiponectin has been shown to acutely improve 
insulin-induced suppression of hepatic glucose production in mice via an associated reduction in 
expression of gluconeogenic enzymes phosphoenolpyruvate carboxykinase (PEPCK) and Glucose-6-
phosphatase (G6Pase; Combs et al., 2001). It is however important to note that although development of 
hyperinsulinaemia is a possible mechanism for the suppression of adiponectin levels,  it seems an unlikely 
mediator of low concentrations as it remains low in later stages of T2DM when insulin levels decrease 
(Maju, 2003).   
 
A systematic review of the relationship between exercise and adiponectin levels was completed by 
Simpson and Sing in 2008. In five reported cross-sectional studies which supported a significant direct 
relationship between physical activity and adiponectin levels in serum, exercise training twice or more 
often per week was associated with adiponectin concentrations of > 4 μg.ml-1.  Adiponectin 
concentrations in subjects with impaired glucose tolerance (4.34 ± 0.28 μg.ml-1) and T2DM (3.42 ± 0.38 
μg.ml-1) were significantly lower than in those with normal glucose tolerance (8.88 ± 0.39 μg.ml-1; p< 





Eleven uncontrolled studies investigating the effects of exercise training with average trial durations of 
19.6 ± 13.4 weeks and consisting of 3.1 ± 1.2 h/week of aerobic exercise (Ryan et al., 2003) or power/ 
resistance training (Oberbach et al., 2006) of moderate-to-high-intensity and low-to-moderate intensities 
reported significant increases in only 3 (27.3%) of the trials  These positive trials revealed an average 
increase in adiponectin of 1.33 ± 2.83 μg.ml-1 in post-training adiponectin levels (Hsieh and Wang, 2005; 
Bluher et al., 2006; Oberbach et al., 2006). Two non-randomized 3-week controlled trials of supervised 
low-to moderately intense cycle ergometer exercise (40 min/day, 5 days/week) in addition to walking 
10,000 steps per day, however showed negligible changes in adiponectin concentrations (Yokoyama et 
al., 2004).  
 
Eight RCTs which averaged 15.3 ± 5 weeks with a mean exercise session time of 2.2 ± 0.5 h/week and 
used moderate–high intensity aerobic exercise (Boudou et al., 2003; Marcell et al., 2005; Balagopal et al., 
2005; Brekke et al., 2005; Giannopoulou et al., 2005), resistance training (Fatouros et al., 2005) or 
combinations of aerobic and resistance exercise (Troseid et al., 2005; Hara et al., 2005), only reported an 
intensity-based dose–response effect in two studies (Fatouros et al., 2005; Marcell et al., 2005).  
Adiponectin levels rose significantly by 21.7 and 61.4% using moderate and high intensity resistance 
training, respectively, while the low-intensity resistance training did not significantly augment 
adiponectin levels (Fatouros et al., 2005).  Marcell et al. (2005) found that high-intensity aerobic exercise 
(80–90% maximum heart rate) was associated with an increase in adiponectin of 0.9 μg.ml-1, whereas 
moderate intensity aerobic exercise elicited an increase of only 0.7 μg.ml-1.   
 
2.9.4 Plasma Brain Derived Neurotrophic Factor 
BDNF is a neurotropin which enhances the survival, growth, maintenance and differentiation of central 
and peripheral neurons (Mattson et al., 2004).  Although it has been shown to be produced primarily by 
the brain, it is also produced by peripheral non-neuronal tissues which include vascular endothelial cells, 
T cells, B cells, monocytes and smooth muscle cells (Rasmussen, 2009).  It has been detected in both 
human plasma and human serum with the brain being the main source of circulating BDNF 
concentrations, contributing as much as 70-80% which is known to be able to cross the blood-brain 
barrier (Rosenfeld et al., 1995; Rasmussen, 2009; Zoldaz and Pilca, 2010). 
 
Functions 
The favorable effects of elevations in brain derived neurotrophic factor (BDNF) are well described 
(Nakagawa et al., 2000: Cuppinin et al., 2007; Krabbe et al., 2007).  These include i) effective lowering 
of blood glucose concentration by enhancing the glucose uptake by skeletal muscle, ii) enhanced 
sensitivity of insulin and iii) increased thermogenic activity and resting metabolic rate (Nakawaga et al., 






In one of the first animal studies, Nakagawa et al. (2000) showed that administration of a small dose of 
exogenous BDNF was found to be effective in lowering blood glucose concentration by enhancing the 
hypoglycaemic action of insulin as well as enhancing energy expenditure. BDNF was also shown to 
enhance insulin sensitivity and improve insulin resistance.  This is accomplished by BDNF acting on the 
brain and central nervous system, especially by acting on its receptor (TrkB) in the hypothalamus.   
 
Krabbe et al. (2007) reported that low levels of BDNF in humans, compared to Nakawaga et al. (2000) 
who used rodents, were accompanied by impaired glucose metabolism and severity of insulin resistance 
concluding that decreased BDNF may be a pathogenetic factor involved in T2DM. It has also been shown 
that serum BDNF concentrations in T2DM patients are significantly lower than in non-diabetic controls.  
This possibly provides another explanation as to why diabetic patients have associated complications such 
as nerve damage as compared to non-diabetics.  Interestingly, it has also been reported that the 




In 2007 Cuppinin published one of the first papers reporting an exercise-induced elevation blood BDNF 
concentrations due to the additional release of BDNF by human contracting skeletal muscle.  BDNF 
mRNA was found to increase 24-48 hours post exercise and return to normal values by 72 hours 
(Cuppinin et al., 2007).  These researchers concluded that BDNF up regulation in exercised muscle may 
be involved in muscle vascularization remodeling and maintenance of neuromuscular junctions.   
 
Although it has been repeatedly shown that single bouts of exercise increase circulating concentrations of 
BDNF (Gold et al., 2003; Rojas-Vega et al., 2006; Tang et al., 2008) and that the magnitude of the 
increase is dependent on the intensity of the exercise (Ferris et al., 2007) with regular training, increments 
are less consistent.  Schulz et al. (2004.a) demonstrated no effect after 8 weeks of aerobic bicycle training 
in individuals with multiple sclerosis whereas Castellano and White (2008) only found a temporary 
increase in BDNF after 4 weeks which returned to pre-training levels after 8 weeks of training. However 
the results reported by Zoldaz et al. (2008) demonstrated a significant increase in BDNF concentrations 
after a 5 week moderate intensity training in young healthy men. Before training the BDNF 
concentrations at rest were 10.3 ± 1.4 pg. ml-1 and post the 5-week training period resulted in a significant 
(p = 0.01) increase in resting BDNF concentrations to 16.8 ± 2.1 pg.ml-1 and BDNF concentration 
exercise induced from 10.9 ± 2.3 pg.ml-1 to 68.4 ± 16.0 pg.ml-1 after training.  
 
2.9.5 Blood Glucose in Rats 
The most common method of determining blood glucose concentration in rats is using a portable 
glucometer on blood collected from a tail vein. Jiu (2010) however showed that the blood glucose tested 





difference of 7-11 mmol.l-1.  The difference of blood glucose between fasting for 5h and 11 h was 0.8 
mmol.l-1. Blood glucose from abdominal aorta was 40% higher than that from tail. The reduction of blood 
glucose was 8% in 60 min and over 50% in 120 min after blood being sampled.  Therefore Jiu (2010) 
suggests that the upper limit for FBG and PBG be expanded to 7.5 mmol.l-1 and 10.4 mmol.l-1, 
respectively.  
 
2.10 Diagnosis of DPN 
 
Up to 50% of DM patients will experience symptoms of peripheral neuropathy such as burning pain, 
shooting or stabbing sensations, paraesthesia, hyperparathesiae and deep aching pain (Gordois et al., 
2003, Boulton et al., 2005).  DPN can present before the diagnosis of DM and it has been estimated that 
patients can have DM for several years prior to their diagnosis (ACFAS, 2013).  Neuropathic pain is 
typically worse at night and symptoms are most commonly felt in the feet and lower limbs, although in 
some cases the hands may be affected (Boulton et al., 2005).  Examination of the lower limb usually 
exposes sensory loss of vibration, pressure, pain, temperature perceptions and absent reflexes.  Patients 
with DM should be screened annually for DPN by examining pin prick, temperature, vibration perception, 
pressure perception and reflexes (Lawrence et al., 2004; Boulton et al., 2005; ADA, 2012). Loss of 
pressure perception and reduced vibration perception predict foot ulceration (Boulton et al., 2005), while 
loss of sensation leads to infection, ulceration and amputation. It has been reported that 80-85% of 
amputations result from non-healing ulcers in diabetic patients with sensory peripheral neuropathy 
(Aszmann et al., 2004).   
 
To determine the degree of peripheral sensory neuropathy the following objective tests can be carried out: 
 
2.10.1 Pressure Perception 
The 10g monofilament is considered one of the most useful tools a clinician can use to test for DPN and 
is recommended by the International DM Federation and the International Working Group on the 
Diabetic Foot.  It remains a useful clinical tool for detecting severe neuropathy and hence identifying 
patients at increased risk of ulceration and amputation (Merriman and Turner, 2002; Tan, 2010).  The 
nerve fibers tested are the A-β group.  The monofilament is applied at right angles to the skin surface with 
just enough pressure to deform the filament into a ‘C’ shape and held for 2 seconds (Figure 2.5, Diagram 
A & B).  The patient is asked to close his/her eyes and to state which foot was touched while the 
podiatrist touches the specified areas as seen in Figure 2.5.  Inability of the patient to detect the 
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Figure 2.5: Using a 10g Monofilament to detect light pressure (Adapted from Diabetes India, 2014) 
 
2.10.2 Vibration Perception 
The nerves fibers tested with a 128Hz tuning fork are the large-diameter A β-fibers that terminate in 
Pacinian corpuscles and are sensitive to rapidly changing pressures or vibrations.  They are coated with 
layers of connective tissue, which has the ability to absorb low-frequency pressure changes, so that only 
high-frequency vibrations such as those produced by the tuning fork would reach the receptors.  As is 
shown in Figure 2.6, the vibrating tuning fork is placed on the skin above a bony prominence such as the 
apex of the hallux, malleolus and the first metatarsal phalangeal joint.  The patient is to describe what 
they feel, without any prompts, as most of the patients are able to feel pressure, but not necessarily 
vibratory sensation (Singh et al., 2005; Merriman and Turner, 2002).   
  
Figure 2.6: The three bony prominences on which sensitivity to the vibration of a Tuning fork is tested 
(Adapted from Caring for Diabetes, 2014). 
 
2.10.3 Sharp/blunt pain Discrimination 
A Neuropen, which is a spring-loaded device delivering a stimulus at a force of 40g and is the safest and 
most reliable method used to test pinprick sensitivity.  As the sharp end cannot pierce the skin (Figure 
2.7) this device assesses the sharp pain pathway, which begins with free nerve endings in the dermis, the 
A-delta fibres, then travels into the spinal cord and synapses in the dorsal horn.  The postsynaptic fibres 
cross to the contralateral anterolateral columns which travel to the brain.  The patients are asked to keep 





their eyes closed and to state which is sharper, the first or the second sensation.  The two ends are 
presented in random sequence to avoid correct guessing by the anxious-to-please participant (Merriman 
and Turner, 2002).  
 
Figure 2.7: A neuropen which is used to assess the integrity of the sharp pain pathway. (Adapted from 
Owen Mumford, 2014)           
  
2.10.4 Temperature Discrimination 
A Tip Therm (a rod-shaped instrument with two ends of different temperatures; Figure 2.8) tests the 
integrity of the temperature receptors that feed the anterior part of the anterolateral columns. The nerve 
fibers involved are the narrow diameter A-delta and C fibers.  The patients are asked to keep their eyes 
closed and are asked to state which side of the Tip Therm feels cooler (Merriman and Turner, 2002).    
 
2.10.5 Light Touch Perception 
The nerves tested are the large-diameter A-β fibres which ascend the dorsal columns that transmit light 
touch perception.  The receptors (Meissner’s corpuscles) lie in the superficial dermis.  The patient is 
asked to keep their eyes close and to state when their foot is lightly stroked with  piece of cotton wool and 
to indicate which foot they feel it on (Figure 2.8) (Merriman and Turner, 2002).   
 
2.10.6 Reflexes 
A patella hammer (Figure 2.8), is used to test for ankle and patella reflexes.  The patellar reflex tests the 
integrity of the spinal reflex pathway (L3, L4) and exhibits descending influences on the ventral horn cell.  
The patient is to relax as much as tension can affect the test and is to sit sideways on the examination 
couch with his/her feet clearing the ground.  A gentle tap on the patellar tendon with the hammer should 
elicit a knee jerk.  The Achilles reflex tests the spinal reflex pathway of the sacral spinal nerves S1 and 
S2.  The response is best elicited when the patients’ foot is in slight dorsiflexion and the Achilles tendon 







Figure 2.8: A Tip Therm placed on the dorsum of the foot. (Adapted from Baehr, 2014) [LEFT]; Cotton 
wool stroked over the dorsum of the foot (Adapted from Soresen et al., 2014) [MIDDLE]; Patella 
Hammer (Adapted from Medipost, 2014) [RIGHT]. 
 
2.11 Physical activity/ exercise and T2DM  
 
As mentioned in the introductory chapter, Sigal et al.(2006) recommend that an accumulation of 
moderate intensity activity >30 minutes on most days of the week, or at least 150 minutes per week, or 
resistance exercise 3 times a week (ADA, 2012), is the most beneficial in managing DM.   
 
In one of the first reported studies, Yeater et al. (1990) examined the effect of a low-to-moderate-intensity 
(69 per cent of maximal heart rate) walking program on lipids, glucose, insulin, HbA1c and 
cardiovascular fitness in randomly assigned control and exercise groups which walked for 40-45 minutes 
three times per week for two months while continuing their usual diets.  A significant improvement was 
recorded in VO2max (from 1.65 to 1.95 l.min-1) with a decrease in resting systolic blood pressure (141 to 
130 mmHg), resting heart rate (88 to 81bpm) and HbA1c in 86% of the exercised group (n=8) after 
training.   
 
2.11.1 Intensity, frequency and duration of exercise programs 
There is a clear causal relationship between the amount of physical activity and coronary artery disease, 
T2DM and MetS (WHO, 2010). The STRIDE study (Slentz et al., 2005; 2007a) demonstrated that body 
weight and visceral fat responded in a dose-response manner to total energy expenditure and that changes 
in exercise intensity alone did also not appear to have any effect on body weight or abdominal fat 
response.  As is summarized in Table 2.2, exercise interventions that have repeatedly shown a decrease in 
HbA1c vary in terms of the duration required to bring about optimal change in HbA1c levels which 
appears to exceed 8 weeks. The ten studies described in Table 2.2 confirmed significantly improved 
glycaemic control following endurance and or resistance training interventions ranging in length from 8 
weeks to 4 months.  This range in duration is also confirmed in the meta- analysis of Thomas et al. (2009) 
on 14 randomized controlled trials in T2DM participants in which the duration of trials ranged from 8 
weeks to 12 months and the exercise interventions significantly improved glycaemic control which are 
attributed to exercise associated decrease in HbA1c as a result of improved glucose utilization.  A meta-





analysis of controlled clinical trials conducted by Boule et al. (2001) also showed that post-intervention 
HbA1c values were significantly reduced in moderate aerobic exercise trials of 8 weeks or less.  The post-
intervention values were 0.66% lower in the exercise group compared to the non-exercise group.  These 
authors stated that a reduction of this magnitude is clinically significant and close to the difference of 
0.9% between conventional therapy and intensive glucose-lowering therapy in the United Kingdom 
Prospective DM Study (UKPDS).  
 
2.11.2 Interval training 
In terms of the recent trend of incorporating high intensity interval training, WHO (2010) initially warned 
that T2DM patients are at a significantly increased risk for coronary artery disease and that a high-
intensity exercise program is an unrealistic choice of management due to the risks associated with 
obesity, older age and sedentary lifestyle (WHO, 2010). Accumulating more recent evidence (Earnest, 
2008; Little et al., 2011; Diabetes.co.uk, 2014) however suggests that interval training has a greater effect 
on many of the cellular mechanisms and offers greater benefits than the traditional aerobic exercise 
intervention involving longer periods of conventional cardiovascular exercise such as continuous jogging. 
It has also been successfully used in younger and older patients who are in a higher risk category. These 






Table 2.2: Exercise Interventions that have confirmed a statistically significant reduction in HbA1c and 
other markers of glycaemic regulation following an aerobic exercise interventions [Kelley and Kelley, 2007; 
Raz et al., 1994; Maoirana et al., 2002; Cauza et al., 2005; Sigal et al., 2007; Ng et al., 2010; Pan et al., 1997; 
Laaksonen et al., 2005; Mc Auley et al., 2002). T2DM: Type 2 Diabetes; DM: Diabetes Mellitus; IGT: Impaired 
glucose tolerance; OGTT: Oral glucose tolerance test] 
 
 Intervention Participants Variables 
examined 
Results 
Raz et al. (1994) 12 wk moderate exercise 
training: 45 min,  3 x wk  
40 participants with 
T2DM, randomly 





Reduction in all plasma levels 
in exercise group (p<0.05) 
Maoirana et al. 
(2002) 
8 wk, circuit training 
program: aerobic and 
resistance exercise  
16 participants with 
T2DM 
HbA1c , FBG Decreases in HbA1c, FBG 
(p<0.05) 
Cauza et al. 
(2005) 
Strength vs. endurance 
training group for 4 
months, three times a 
week 
Randomized 
controlled trial of 22 
patients with T2DM 
doing resistance 
training or aerobic 
training  
HbA1c Average decrease of 0.3% in 
HbA1c of aerobic training 
group  
 
Sigal et al. (2007) 4 exercise groups:  
 resistance 
 aerobic 




Randomized trial of 
previously inactive 
patients with T2DM  
HbA1c 0.43% reduction in HbA1c of 
in aerobic training group. No 
change in HbA1c levels with a 
further increase in duration 
(p>0.05) 
 








3234 participants at 
high risk of 
developing DM; 




onset of DM 
by OGTT 
Modest increases in physical 
activity reduces the incidence 
of DM by 58%. Lifestyle 
change is twice as effective as 
MF therapy in preventing the 
progression to DM  
Ng et al. (2010) Resistance exercise vs. 
aerobic exercise  
(control) groups  
 
Randomized trial of 
60 T2DM participants 
HbA1c Decrease of 0.3% over the 8 
week period in aerobic 
exercise group  
 
Pan et al. (1997) 3 groups: 
 control  
 exercise only 
(EG) 
 diet only (DO) 










Incidence of DM decreased by 
33%, 47% and 38% in the 
DO, EG and DE groups 
respectively. Efficacy of diet 
similar to that of exercise; no 
additional benefit gained from 
combining diet and exercise 
Laaksonen et al. 
(2005) 
Leisure time-physical 
activity (LTPA) >4 
hours/week of moderate 
exercise 
and diet modification 
 
Randomized control 






Reduced risk of developing 
DM by 58%  
Mc Auley et al. 
(2002)  
4 intervention groups: 
 control  
  modest diet &  
exercise  
 intensive diet &              
exercise (ID&E) 
Randomized control 











Greater improvement in 
insulin sensitivity in ID&E 







2.11.3 The effect of exercise alone versus combined dietary and exercise intervention? 
Although a number of studies detailed in Table 2.2 have supported the effectiveness of exercise alone in 
improving glycaemic control in T2DM participants, the majority have combined the exercise intervention 
with a dietary intervention which consisted of a low fat, low refined carbohydrate or prudent diet (Pan et 
al., 1997; Mc Auley et al., 2002; Knowler et al., 2002; Laaksonen et al., 2005). Umpierre et al. (2011) 
confirmed that physical activity is only beneficial if combined with dietary recommendations, and 
structured exercise of greater than 150 minutes per week was associated with the greatest decrease in 
HbA1c.  A Cochrane review (Oronzo et al., 2009) on preventing T2DM concluded that physical activity 
interventions (on average, at least 150 minutes each week of brisk walking, cycling or jogging) with diet 
modification reduced incidence of DM by 37% in high-risk groups such as people with MetS and 
reported improvements in  body mass, waist circumference and blood pressure.  Carroll and Dudfield 
(2004) in a meta- analysis review of randomized control trials of metabolic abnormalities and exercise 
concluded that there is evidence that long-term exercise, without weight reduction, only modestly 
decreases abdominal adipose tissue and improves insulin action among overweight obese adults.  In 
addition, these authors provided evidence that when exercise alone has shown to be effective in 
improving impaired glucose control and reducing the incidence of T2DM, it was associated with modest, 
but clinically relevant lipoprotein profile improvements in raising HDL-C and lowering triglycerides and 
modest reductions in blood pressure with greatest changes evident in overweight individuals with 
hypertension.  However, exercise did not alter total cholesterol and LDL-C concentrations. It was 
concluded that more evidence is required on the effects of exercise alone (Carroll and Dudfield, 2004).   
 
2.12 HbA1c and Exercise 
 
The exercise-training associated decrease in HbA1c reported in the studies summarized in Table 2.2, has 
been associated with improved glucose utilization via previously described GLUT4- mediated glucose 
uptake and insulin-regulated glucose transport in adipose tissues, skeletal and cardiac muscle (Earnest et 
al., 2008).  While an acute bout of endurance exercise has been shown to provide a strong stimulus for 
mitochondrial biogenesis that increases GLUT4 concentration as contraction of the skeletal muscle 
stimulates the cell to translocate GLUT4 receptors to the surface, thus facilitating muscle glucose 
transport (Huang and Czech, 2007; Earnest et al., 2008), it is also proposed that GLUT4 protein 
expression increases with regular endurance exercise and that impairment in GLUT4 transport/ 
translocation may be the cause of insulin resistance (Earnest, 2008). Apparent cross talk between 
inflammatory and metabolic signaling by means of downstream mediators and signaling pathways, has 
also been reported (Earnest, 2008).  These signaling effects are associated with impaired phosphorylation 
of Akt substrate 160 which is the first step identified in the insulin signaling cascade regulating GLUT4 






The possible mechanisms responsible for the reduction in HbA1c (improved glucose control) due to 
exercise are further explained by Jensen and Richter (2012).  Plasma glucose and muscle glycogen are 
important fuels for exercise and the increase in muscle glucose uptake during exercise is dependent on the 
delivery of glucose as a result of increased capillary perfusion and plasma glucose concentration as well 
as increased permeability of the muscle membrane.  Muscle glycogen utilization is dependent on exercise 
intensity and duration and is controlled by the activity of glycogen phosphorylase and the concentration 
of glycogen and inorganic phosphate ions.  In post-exercise recovery, muscle glucose uptake has 
increased sensitivity to insulin therefore increasing post prandial glucose uptake by previously active 
muscles.  The molecular mechanism during exercise involves GLUT4 transporter which enables the 
movement of glucose into cells without the necessity of insulin being present.  Furthermore, insulin 
sensitization may be attributed to an exercise-induced phosphorylation of proteins (TBC1D4 and p38 
MAPK), which remain phosphorylated for hours post exercise (Jensen and Richter, 2012). 
 
Although, as detailed in Table 2.2, ten studies confirmed an decrease in HbA1c  and the incidence of the 
onset of DM after ≥ 8 weeks of exercise training alone, numerous studies (Oronzo et al., 2009; Umpierre 
et al., 2011) have failed to confirm an improvement in glycaemic control in T2DM participants following 
an intervention consisting solely of exercise.  Burns et al. (2007) have explained that certain DM 
susceptibility genotypes might predispose individuals to respond or not to respond positively to exercise.  
It is possible that participants with early-onset T2DM (and severe obesity) have either genetic or acquired 
factors that result in resistance at the level of the skeletal muscle and are related to mitochondrial 
dysfunction. Burns et al. (2007) also reported that the failure to increase VO2max in diabetic participants 
is consistent with the presence of mitochondrial dysfunction. 
 
Further studies are needed to be conducted to address these conflicting results, which are so important for 
the development of effective treatments for these high-risk patients. 
 
2.13 Physical activity/ exercise for the treatment of DPN 
 
It is important to decrease HbA1c levels as it is associated with a higher risk of developing retinopathy, 
nephropathy, cardiovascular disease and/or damage to nervous tissue or neuropathy (Topiwala, 2012; 
Boulton et al., 2005).  The first step in managing DPN is therefore to achieve and maintain optimal 
glycaemic homeostasis (Boulton et al., 2005).   
 
Although there is much evidence confirming the beneficial effects of different exercise modalities on 
glucose control in T2DM patient, little evidence exists of an association between physical exercise and 
sensory neuropathy and, to the authors knowledge, only one research report focusing on the benefits of 
exercise on DPN has been completed to date.  A study by Gurney (2011) demonstrated quantifiable 





diabetic participants with DPN.  A significant improvement in sensory threshold was noticed at three of 
the four tested foot sites as well as for the average foot sensory threshold.  The finding of improved 
sensory threshold in this study is unique, as it is the first study in which a group of neuropathic 





The possible associations between the effects of exercise on DPN and between exercise-induced changes 
in DPN and exercise-induced changes in circulating HbA1c, BDNF and adiponectin concentrations levels 
are thus an open area for future investigation. As preliminary work has not yet been completed, the need 











This work consisted of two components.  Firstly a clinical trial was conducted on human 
participants and thereafter elucidation of possible mechanisms was investigated following an 
exercise intervention on rodents. 
  
PART ONE: CLINICAL TRIAL ON HUMAN PARTICIPANTS 
 
3.1 Research Design of Human Study 
 
The study design was a prospective cohort design with diabetic participants and a CG.  Pre and post-
intervention measurements were taken and every attempt was made to regulate possible extraneous 
variables which could invalidate the results of study or result in a type 11 error. 
 





3.2 Ethical Approval and Inclusion Criteria for Human Study 
 
Ethical approval to undertake this study (Appendix A) was obtained from the Biomedical Research Ethics 
Committee of the University of KwaZulu –Natal (Clearance No: BFC 055/13).  The following inclusion 
criteria were set for participants in the study:  
 Type 2 diabetic participants diagnosed with DPN 
 Age Range: 34 and 48 years  
 Using medication for the treatment of existing co-morbidities and oral anti-diabetic agents for the 
management of T2DM 
 Less than an hour a week of exercise in the 3 months prior to the study 
 Willingness to participate in the entirety of the trial, which includes the regular exercise 
intervention and laboratory testing  














Participants were randomly chosen from the available database of the private podiatry company for which 
the PI worked (Anette Thompson and Associates).   
The selected 79 participants were phoned and asked if they would like to be a part of the study.  Once 
verbal consent was obtained from the participants they were invited to attend the baseline assessment in 
the Exercise Physiology Laboratory of the Division of Human Physiology of the School of Laboratory 
Medicine and Medical Sciences of the University of KwaZulu-Natal. 
  
3.3 Pre-Trial Assessment 
 
3.3.1 Initial recruitment 
Each participant was firstly given an information sheet (Appendix B) which fully outlined the purpose of 
the study, detailed the commitments expected, assured the participants that they may leave the trial at any 
time and required any illness or adverse effects of the trial to be reported urgently.  An informed consent 
form (Appendix C) was signed by each participant and thereafter, further more careful screening was 
conducted on those who met the inclusion criteria and had enrolled for the study.   
 
3.3.2 Further Screening 
This firstly included completion of a general baseline questionnaire to assess their i) general health status, 
ii) lifestyle and iii) physical activity and whether they were able to exercise without causing exercise-
induced complications (Appendix D).  The information provided was verified by a medical practitioner 
who interviewed each participant and conducted a brief physical examination and assessment of vital 
signs, before the questionnaire was submitted. 
 
3.3.3 Laboratory Testing  
An exercise physiologist recorded the anthropometric measures which included body mass (kg) and 
height (cm) in light clothing without shoes and stature (cm) using an AdamLab electronic scale (JPS-
2030, (Adam equipment, Connecticut, USA)) and custom-built stadiometer, respectively.  Waist 
circumference was measured as the lowest reading of the girth, midway between the lateral lower ribs and 
iliac crest using a tape measurer.  Percentage body fat was calculated from the sum of four skinfold 
thicknesses (biceps, triceps, subscapular and suprailiac) using the technique described by Durnin and 
Womersley (1974).   
 
The physician recorded the participants’ vital signs i.e. blood pressure, resting heart rate, temperature and 
respiratory rate.  Other examinations included assessing the cardiovascular system for abnormal heart 
rhythm and murmurs and the respiratory system for abnormal breathing sounds. Possible infections and 





for any musculoskeletal problems that may have affected the compliance in the 8-week exercise 
intervention.    
 
A 5ml venous blood was drawn by the physician into two Ethylenediaminetetraacetic Acid (EDTA) 
vacutainer tubes.  One sample of whole blood was sent in to the local pathological laboratory (Ampath 
Laboratories, Westridge, Durban) and analysed for HbA1c.  The remaining blood sample was 
immediately spun at 3000rpm for 5 min at 4˚C and the plasma was stored at −80˚C for later analysis of 
BDNF and Adiponectin concentrations using ELIZA kits (R&D Systems, Minneapolis, MN, USA and 
ADIPOQ, Abnova Corporation, Taiwan).   
 
3.3.4 Nerve Function Testing 
Thereafter peripheral sensory neuropathy status was assessed by a qualified podiatrist (B.  Tech Pod).  
This included a questionnaire to assess their subjective perception of the participants in terms of the 
degree of sensory peripheral neuropathy symptoms they were experiencing at the onset of the trial (i.e. 
burning sensation, pins and needles, numbness and/or aching pain).  The signs of sensory peripheral 
neuropathy were subsequently quantitatively assessed using the tests described below.   
 
The Monofilament test 
A 10g monofilament was applied at right angles to the skin surface with just enough pressure to deform 
the filament into a ‘C’ shape.  The monofilament was held for 2 seconds at each of the ten locations 
specified in Figure 3.1.  Participants were asked to keep their eyes closed and to state which foot was 
touched while each of the areas specified in Figure 3.1 was tested for integrity of the A β group of nerves 
and its sensitivity to the application of light pressure.  The number of positive findings for each of the 10 










     
Figure 3.1: Using a 10g Monofilament (ABOVE) at appropriate sites (BELOW) 
 
The Vibration test 
A 128Hz tuning fork was used to test the ability to identify vibratory sensation.  The vibrating tuning fork 
was placed on the skin above the bony prominences of the apex of the hallux, the medial malleolus and 
the first metatarsal phalangeal joint (Figure 3.2).  The participant described what they felt, without any 
prompts, in order permit the tester to differentiate between the ability of participants to feel pressure, 
versus feeling the actual vibratory sensation. The number of positive findings for a total of 6 sites on the 
two feet was used to allocate a score for this test (Table 3.2). These sites include the 1st 
metatarsophalangeal joint, medial malleoli and apex of halluces. 
          
Figure 3.2: The use of a Tuning fork on a bony prominence [LEFT]; Neuropen using the sharp/ blunt 
application [MIDDLE-LEFT]; Tip Therm placed on the dorsum of the foot [MIDDLE-RIGHT]; testing 






Sharp Pain Pathway Test 
A Neuropen which has a sharp and a blunt end (Figure 3.2) was used to assess the integrity of the sharp 
pain pathway.  The participants were asked to keep their eyes closed and to state which of the two ends 
presented, felt sharper.  The two ends were presented in random sequence to avoid correct guessing by the 
anxious-to-please participant.  The number of positive findings for a total of 4 sites (dorsum and plantar 




A Tip Therm with warm and cool ends (Figure 3.2) was placed on the dorsum and plantar surface of the 
foot in order to test the integrity of the temperature receptors.  The participants were asked to keep their 
eyes closed and state whether the first or the second end placed on the dorsal and plantar surfaces of the 
foot, felt cooler.  The number of positive findings for a total of 4 sites on any part of the dorsal and 
plantar surfaces of the two feet was used to allocate a score for this test (Table 3.2) 
 
Light Touch Test 
The participants were asked to keep their eyes closed.  They were then asked to indicate whether they felt 
the light stroking of a piece of cotton wool on the left or the right foot (Figure 3.2). The number of 
positive findings for a total of 4 sites on any part the dorsal and plantar surfaces of the two feet was used 
to allocate a score for this test (Table 3.2) 
 
Ankle and Patella Reflex Test 
A patella hammer (Figure 3.3), was used to test for ankle and patella reflexes in the lower leg and foot.  
The participants were asked to sit sideways on the examination couch with their feet clearing the ground 
and to be relaxed as possible.  A gentle tap on the patellar tendon with the hammer was used to determine 
whether it elicited a knee jerk.  The intactness of the ankle reflex was tested by holding the foot in slight 
dorsiflexion and tapping the Achilles tendon with the hammer. 
   





The number of positive findings for a total score of 8 of both feet for this test.  If the reflex was absent a 
score of 0 was given, if diminished a score of 1 was given and if the reflex was present a score of 2 was 
given.  (Table 3.2) 
 
Quantification of nerve function 
As is shown in Table 3.2 , the values obtained for the above-mentioned six tests were added and 
presented as a percentage of the sum (n=46) in order to reach an overall value which reflected overall 
nerve function in the feet of the participants. 
 
Table 3.2: Quantification of nerve function 
 
Instrument used Findings marked out of (per 
foot/ leg) 
Total possible points allocated 
for both feet 
10g Monofilament 10 sites 20  
Vibration 3 sites 6  
Neuropen 2 sites 4  
Tip Therm 2 sites 4  
Cotton wool 2 sites 4  
Patella Reflex  
 
Present – 2 
Diminished – 1 
Absent – 0 
Present – 4 
Diminished – 2 
Absent – 0 
Ankle Reflex 
 
Present – 2 
Diminished – 1 
Absent – 0 
Present – 4 
Diminished – 2 
Absent – 0 
 
3.4 The Exercise Intervention 
 
Those participants who qualified for participation the study, were then invited to begin with the exercise-
intervention.   Their age-related maximum heart rate (MHR) was calculated according to the formula of 
Tanaka et al. (2001) i.e.  MHR = 208 - 0.7 x age, in order to facilitate the monitoring of the exercise 
intensity of the participants.  The exercise programme consisted of low impact interval type exercise on 
spinning bikes which had cleated pedals that ensure that the pressure on the toes was minimized while 
cycling (Figure 3.4).   
 
A 30-minute spinning class was completed three times a week for 8 weeks under the supervision of a 
qualified spinning instructor.  This was completed by the group on “spinning bikes” in an environmental 
controlled exercise laboratory in the Prime Human Performance Institute at the Moses Mabida Stadium.  





record the heart rates and RPE during the class.  Monitoring of the participants heart rate ensured that the 
heart rate was kept within a range of 60-80% of their previously calculated age-related maximum heart 
rate.  The basic structure of a typical class session is provided in Table 3.3.  
 
Table 3.3: Training protocol used by the active participants 
PHASE DURATION DESCRIPTION 
Warm-up ± 5 min Relaxed cycle with low resistance against flywheel  and 
comfortable cadence( 55-65 rpm) maintaining 60% MHR and RPE 
of 4-6 
Training phase A ± 2-3 min  Seated climb: every 20 seconds  the participant increased the 
resistance by 1 level until reaching a level  which elicited a heart 
rate of 80% MHR and RPE of 8-10 
Training phase B  5 - 8 min Active recovery interval:  Resistance reduced until workload was 
equal to that of warm-up.  Duration was dependant on time taken 
for heart rate to drop to 60% MHR and RPE to reach 4-6 
Training phase C 4-10 min  
 
Short fast spinning repetitions:  3-6 x 30sec repetitions of 
rapidly increasing cadence until close to maximal RPE (>8)  and 
80% MHR was reached with 20-60 sec recovery intervals 
permitting the heart rate to drop to 60% MHR and RPE to reach 4-
6 
Warm-Down 5-8 min Relaxed cycle with low resistance against flywheel and 
comfortable cadence, maintaining 60% MHR  and RPE of 4-6 
rpm: revolutions per minute; MHR: maximum heart rate (Tanaka et al., 2001) ; RPE: Rate of Perceived Exertion 
(Borg, 1982) 
As the participants became fitter the level of difficulty of the spinning class was increased, by increasing 
the workload intensity, reducing the duration of recovery intervals and increasing the number of training 
repetitions.  At all times, a medical doctor, specialized in Sports Medicine, and was on standby to manage 
any adverse event or possible complications that may have arisen.   
 
Figure 3.4: The positioning of the foot within the pedal that has straps to ensure that pressure on the toes 





3.5   Post-Trial Assessment 
 
The post-assessment was concluded 4 days after the exercise intervention had been completed.  A post-
trial questionnaire (Appendix E) was completed, the anthropometric measures taken at baseline were 
repeated and each participant was re-assessed by a physician. The level of peripheral sensory neuropathy 
was determined by the same qualified podiatrist who did the pre-training assessments (page 31).  A 5ml 
venous blood sample was drawn into the EDTA tubes by the physician for the later assessment of blood 
HbA1c, plasma BDNF and adiponectin concentrations.  The samples were processed as previously 
described on page 31 for the pre-assessment.   
 
3.5.1 Biochemical Analyses 
 
3.5.1.1 Plasma BDNF 
Plasma BDNF was determined using a sandwich enzyme immunoassay kit (BioAssayTM ELISA Kit) 
(United States Biological, Swampscott, Massachusetts).   
 
The procedure was as follows: 
 
1. The stock Standard solution was made by adding 1.5ml of Standard/Sample diluent to the 
BDNF Standard.  950µl of standard/sample diluent was placed into an eppendorf tube #1 and 
50 µl of the stock Standard solution added. Six further even serial dilutions were then 
prepared by adding assay diluent to the stock standard as shown in Figure 3.5. 
 
Figure 3.5: Serial Dilution of Standard 
 
2. 100uL of each standard (500, 250, 125, 62.5, 31.25, 15.63, 7.82 pg/mL) and sample 
diluted with sample diluent (1:2 dilution factor) were then placed into the wells of the plate 
that had been pre-coated with rabbit anti-human BDNF polyclonal antibody  in 
duplicate.  





4. The plate washed 4 times by placing 250ul of diluted wash buffer/ diluted water using a 
multi-channel pipette and then blotted on clean paper towel. 
5. Immediately before use the B2700-08E: Mab (Biotin) was be prepared.  The biotinylated was 
diluted 1:1000 with B2700-08C.  100ul of the diluted Biotin was added to each well.  The 
plate was then covered and incubated at room temperature for 2-3hours on a shaker.  Step 4 
was repeated. 
6. Immediately before use the B2700-08F: Streptavidin was diluted 1:1000 with B2700-08C.  
100ul of the diluted streptavidin (HRP) solution was added to each well.  The plate was 
covered and incubated at room temperature on a shaker for 1 hour.  Step 4 was repeated. 
7. The B2700-08G: TMB/E Solution was warmed to room temperature and 100ul of TMB/E 
Substrate was added to each well.  The plate was incubated at room temperature for 15 
minutes.  Then 500pg/ml standard was added creating a deep blue colour.  The reaction was 
then stopped by adding 100ul B2700-08H. Stop Solution to each well.  The blue colour 
changed to yellow.  The plate was immediately read at 450nm on a plate reader (Spectrostar 
nano BMG Labtech, Germany).   
8. The results were calculated with using a plate reader/ plate interface.  The data was entered 
into the computer program curve fitting software.  A fit was obtained for the standard 



















Figure 3.6: Standard Curve for BDNF assay 
 
3.5.1.2 Plasma Adiponectin 
In the ADIPOQ (Human) ELISA Kit, adiponectin concentration was determined using a sandwich 
enzyme immunoassay kit (Abnova Corporation, Taiwan).   
The procedure for each plate was as follows: 
1. 100 μl of Standards (5-100 ng.ml-1 for plasma samples), Dilution Buffer (Blank) and human 
plasma samples (diluted 300x with the Dilution Buffer prior to the assay) was pipetted into the 





2. The plate was incubated at room temperature (25°C) for 1 hour, and placed on an orbital 
microplate shaker at 300 rpm. 
3. The wells were washed 3 times with Wash Solution (0.35 ml per well).   
4. 100 μl of Conjugate Solution was added into each well. The plate was incubated at room 
temperature for 1 hour and placed on an orbital microplate shaker at 300 rpm. 
5. The wells were washed again 3 times with Wash Solution (0.35 ml per well).   
6. 100 μl of Substrate Solution was added into each well and the plate was incubated for 10 minutes 
room temperature.  The colour development was stopped by adding 100 μl of Stop Solution. 
7. The absorbance of each well was determined using a microplate reader set to 450 nm, with the 
reference wavelength set to 630 nm.   The readings at 630nm were subtracted from the readings 




















Figure 3.7: Standard Curve obtained for Adiponectin assay  
 
3.5.2    Statistical Analyses 
 
In the AG, data obtained were expressed as means ± SD as well as range and analysed using pre-post 
paired t tests and an SPSS version 15.0 (SPSS Inc., Chicago, Illinois, USA) program.  Alpha was set at 
0.05 and the level of confidence at 95%.  As directionality could not be assumed beforehand, two-tailed 
tests were used.   
 
             No statistical analyses were conducted on the control subjects (n=2). Data were presented as mean (±SD) 






PART TWO: ANIMAL WORK FOCUSSING ON POSSIBLE MECHANISMS 
 
                   3.6   Ethical Clearance for Rodent Work 
 
This protocol was approved by the Animal Ethics Sub-committee, University of KwaZulu-Natal Ethics 
Committee, Pietermaritzburg Campus and ethics number 102/13/Animal was allocated to this project. 
 
3.7   Housing, Grouping and Induction of Diabetes in Rats 
 
3.7.1 Housing and Grouping 
Six-week-old Sprague-Dawley rats with a mean body mass of 219.3 ± 7.0g were obtained from the 
Biomedical Research Unit at the University of KwaZulu-Natal.  They were randomly divided into 3 
groups: (1) Normal control (NC), (2) Diabetic control (DBC), and (3) Diabetic exercise (DBE) (Table 
3.4).  The animals were housed in transparent polycarbonate cages in a temperature and humidity-
controlled room with a 12 h dark-light cycle in accordance to the rules and regulations of the University 
of KwaZulu-Natal Experimental Animal Ethics Committee.  The animals were fed rodent ripe meadow 
feed ad libitum during the 10 week experimental procedure.   
 
3.7.2 Induction of Diabetes 
NC were supplied with normal drinking water ad libitum whilst DBC and DBE were supplied with 10% 
Fructose (FR10) solution ad libitum for the initial 2 weeks only, and thereafter were given normal 
drinking for the rest of the experimental procedure.   
 
Table 3.4: Summary of animal models 
 
GROUP 1 GROUP 2 GROUP 3 
n=7 n=6 n=7 








At the start of week 3, NC group was injected with a vehicle buffer only (i.p) whilst DBC and DBE were 
injected with 40mg/kg body mass (BM) of Streptozotocin (STZ) after an overnight fast. 
 
3.8   Confirmation of Diabetes 
 
A week following STZ injections, blood glucose levels were measured after a 3 h fast using a portable 
glucometer (ONETOUCH SelectTM) via blood collected from a tail vein.  All animals with a blood 





for pre-diabetes was >12 mmol.l-1. Weekly 3 h fasting blood glucose (3HFG) concentrations were 
obtained throughout the remainder of the experimental procedure.   
 
3.9   Fluid and food intake and body mass 
 
Daily food and water intake were obtained from each rat throughout the experiment, but averaged per 
week to note any changes observed.  Mass was measured every week.   
 
3.10   Treadmill training of rats 
 
A motorized custom-made treadmill obtained from the Department of Physiology at the University of 
KwaZulu-Natal Westville campus, was used for the exercise protocol.  DBE and PDBE rats were given a 
2 week acclimation period which began with a speed of 16m.min-1 maintained for 15min. Thereafter the 
speed and duration were increased reaching 20m.min-1 for 55min by the end of the 2nd week after which 
the 5-week exercise program commenced. 
 
3.11   Collection of blood 
 
After a 6/7 hour fast all animals were euthanized using Halothane to the extent of the 4th stage of 
anaeasthesia.  The blood collected via cardiac puncture was equally dispensed into pre-cooled Vacutest 
tubes (EDTA tubes).  Plasma blood samples were immediately centrifuged at 3000rpm at 3-4°C for 4min.  
Plasma was then pipetted off and dispensed into eppendorf tubes and dropped into liquid nitrogen.  
Thereafter plasma samples were placed in an ultrafreezer from the Department of Physiology until 
analysis was done. 
 
3.12   Biochemical Analyses 
 
3.12.1 Plasma BDNF  
Plasma BDNF was determined using a sandwich enzyme immunoassay kit (BioAssayTM ELISA Kit) 
(United States Biological, Swampscott, Massachusetts) as described in 3.5.1.1.  The procedure for each 
plate was identical to that used for human plasma samples excepting for a change in the dilution factors. 
Rodent plasma samples were diluted using a 1: 3 dilution factor and added to the wells in triplicate. 
 
3.12.2 Plasma Fructosamine 
Plasma fructosamine was analyzed using LabMax Plenno Automated Chemistry Analyzer. Plasma 
samples were transferred to eppendorf tubes and placed into the refrigerated compartment of the analyzer 






3.12.3 Plasma Insulin  
A solid phase two site ELISA based on direct sandwich technique in which two monoclonal antibodies 
are directed against separate antigenic determinants on the insulin molecule, was used (DRG 
Ultrasensitive Rat Insulin ELISA kit-(EIA-2943; DRG International Incorporated).   
1. After 25uL of prepared standards and undiluted plasma samples had been added to the 96 
microtitration wells precoated with anti-insulin antibodies in triplicate, 100uL of peroxidase-
conjugated mouse monoclonal anti-insulin (enzyme conjugate11X; brought to RT) was added to 
each well.   
2. The plate was incubated on an automatic shaker (150rpm) for 2 hours at room temperature to 
allow for the insulin in the standards and samples to react with the anti-insulin antibodies bound 
to the well.   
3. After the reaction volume was discarded, 350uL of wash buffer solution was added to each well 
using a multipipette.  The plates were tapped firmly several ties against absorbant paper to 
remove excess liquid.  This washing step which removed remaining unbound enzyme labelled 
antibody, was repeated 5 times.   
4. 200 uL of TMB/E solution substrate (brought to RT) was added and the plate was incubated for 
15 minutes at room temperature in order to detect the bound conjugate remaining on the walls of 
the wells.   
5. 5 uL of stop solution (0.5M H2SO4) was added to each well and after the plate was  placed on the 
shaker for 5 seconds to ensure mixing, the optical density was measured at 450 nm on a   
microplate spectrophotometer (Spectrostar nano BMG Labtech, Germany). 
6. Using the plate reader/ plate interface, the data was entered into a computer program curve fitting 



























3.12.4 Plasma Adiponectin 
As previously described for humans, an ADIPOQ ELISA Kit (Abnova Corporation, Taiwan) was used.  
The procedure for each plate was identical to that used for human plasma samples excepting for a change 
in the dilution factors. Rodent samples were diluted using a 1:100 dilution factor and the samples were 
added to the wells in triplicate.  
 
3.13   Statistical analyses of data in rodent work 
 
All data was presented as means (±SD) and analysed using Graph Pad Prism 5 software (version 5.01, 
2007).  For comparison of the means of weekly measurements in the three groups, a repeated measure 
analyses of variance (ANOVA) was used, whereas a one way ANOVA was used for comparison of the 
post-trial means of the NC, DBC and DBE groups.  In the case of significance being detected, ANOVAs 













Of the 79 diabetic patients from the private podiatry practice (Anette Thompson and Associates) who met 
the inclusion criteria and received a phone call inviting them to participate in the study, only thirteen (ten 
active and 3 controls) agreed to enroll for the programme.  Of these thirteen diabetic participants who 
were originally recruited as participants in the study, one control participant was unable to continue with 
the program due to health reasons, one active participant acknowledged having been active prior to the 
study and was permitted to continue with the study as an active control (AC) and by the end of the 7th 
week an active participant was unable to complete the exercise program due to work commitments.  The 
final numbers of compliant participants therefore constituted an active group (AG) of eight, a control 
group (CG) of two and one active control (AC).  Participants in the AG ranged from 34-47 years with a 
mean (± SD) age of 40.1 (±4.6) years, the CG ranged from 45-46 years with a mean (±SD) of 45.5 
(±0.71) years and AC was 40 years of age.   
 
4.2 Medical History and Lifestyle 
 
From the baseline questionnaire, it was ascertained that all participants were not experiencing symptoms 
indicating the presence of viral or bacterial infections at the start of the exercise program.  Only two of 
the active participants and one control participant reported experiencing symptoms of a general cold, 
three months prior to the study. 
 
None of the participants had been diagnosed with conditions which have been shown to result in sensory 
peripheral neuropathy, but not be related to diabetes, such as heavy metal poisoning, vitamin B12 
deficiency, renal disease, chronic inflammatory demyelinating neuropathy, inherited neuropathies or 
vasculitis.    
 
All participants in the study (n=11) made use of prescribed oral anti-diabetic medication which included 
a hypoglycemic agent which suppresses hepatic glucose production (Metformin HCL; n=7) and/or 
Glipizide (n=4) which acts to increase insulin sensitivity by binding to sulphonylurea receptors on the 
surface of the pancreatic β-cells.  They undertook not to change the brand of medication, dosage and 





reported being previously diagnosed with hypertension and using anti-hypertensive medication.  Another 
two participants were previously diagnosed with hypothyroidism and treated with Eltroxin.  None were 
smokers.  Three (37.5%) reported to drink an average of six tots of spirits and/or six beers a week.  The 
caffeine intake included six participants (75%) drinking between 1-3 cups of coffee per day and four 
(50%) participants consuming 1-3 cups of tea a day.  All, excepting AC, confirmed not to have previously 
taken part in scheduled exercise for more than one hour per week.  Three participants consumed a high 
carbohydrate and low fat diet, four a prudent diet (low refined carbohydrates, transfat and saturated fat 
content) and one was a lacto-vegetarian.    
 
The two control participants were both diagnosed and managed for hypertension prior to the study.  One 
was a smoker, smoking up to five cigarettes a day and one control participant only drank during social 
occasions.  One participant reported drinking 1-3 cups of coffee per day and two participants drank 1-3 
cups of tea a day.  One consumed a prudent diet and the other consumed a high carbohydrate- low fat 
diet, but both were cautious regarding their intake of refined carbohydrates/ high sugar containing foods.    
  
In terms of their post-trial questionnaire, participants confirmed that they had maintained a similar diet 
throughout the intervention.  The AG confirmed they had complied with exercise requirements of the 
program, whereas the control participants had refrained from participating in any regular structured 
exercise before or during the program and AC had maintained his usual thrice weekly endurance exercise 
programme.    
 
Of the eight neurological symptoms experienced in the feet, the AG reported 50% improvement, however 






Table 4.1: Reported number of participants expressed as percentage incidence of pre and post study 
neurological symptoms experienced in the feet in the active (n=8), control participants (n=2) and active 
control (n=1) 
SYMPTOMS AG 
PRE - POST 
% (N) 
CG 
PRE - POST 
% (N) 
AC 
PRE - POST 
% (N) 
BURNING PAIN 25 (n=2)  37.5 (n=3) 100 (n=2)  50 (n=1) 0 (n=1) 0 (n=1) 
SENSITIVE TO TOUCH 25 (n=2)  12.5 (n=1) 50 (n=1)   0 (n=0) 0 (n=1) 0 (n=1) 
PINS AND NEEDLES 25 (n=2)  12.5 (n=1)  50 (n=1)  0 (n=0) 0 (n=1) 0 (n=1) 
ABLE TO DISTINGUISH 
BETWEEN HOT AND 
COLD WATER ON FEET 
25 (n=2)  37.5 (n=3) 50 (n=1)   0 (n=0) 0 (n=1) 0 (n=1) 
NUMBNESS 12.5 (n=1) 12.5 (n=1) 50 (n=1)   0 (n=0) 0 (n=1) 0 (n=1) 
SYMPTOMS WORSE AT 
NIGHT 
12.5 (n=1)  25 (n=2) 50 (n=1)   0 (n=0) 0 (n=1) 0 (n=1) 
ABLE TO SENSE FEET 
WHEN WALKING 
12.5 (n=1)  25 (n=2) 50 (n=1)   50 (n=1) 0 (n=1) 0 (n=1) 
LEGS HURT WHEN 
WALKING 
37.5 (n=3)  37.5 (n=3) 50 (n=1)  0 (n=0) 0 (n=1) 0 (n=1) 
 
4.2.1 General Medical Assessment 
Results of the medical examination and assessment of their vital signs, conducted by a medical physician 
at the start of the baseline assessment, indicated that participants did not present with symptoms which 
excluded them from the program.    
 
One of the active participants, presented with angular stomatitis around the mouth, one with anhidrotic 
feet and slight L4/L5 facet joint pain.  A control participant had mentioned the possible diagnosis of 
Morton’s neuroma and another control participant reported to have paraesthesia in both feet and the 
doctor identified fine crepitation during breathing.  All participants (n=10) were permitted to continue 
with the study.     
 
4.2.2 Physical Characteristics 
The physical characteristics of the active and control participants at baseline (pre-trial) and post- trial are 
presented in Table 4.2 and 4.3, respectively.  Although pre-exercise intervention mean ( SD) body fat 
percentage and BMI dropped marginally for the active participants following the intervention, these 
reductions in the active participants were not statistically significant (p>0.05). The mean ( SD) resting 
heart rate measured in the active participants prior to the exercise intervention was 79.0 bpm  7.9 and 





measured in the active participants prior to the exercise intervention was 136/94mmHg ( 10.2/13.4) 
which reduced to post exercise intervention to 126/91mmHg ( 7.4/13.4) and showed a significant change 
in the systolic resting blood pressure (SBP; p=0.043).  
 
Table 4.2: Physical Characteristics of the Active Group (AG) (n=8)  
Characteristics 
AG 








Mass (kg) 91.5 ±22.5 61.4-130.4 91.4 ±22.6 62.5-131.7 
Stature (cm) 172 ±0.1 155-190 172 ±0.1 155-188 
Percentage Body Fat* 34.2 ±5.7 27.5-43.0 33.4 ±4.6 26.0-38.6 
Body Mass Index (kg.m-2) 30.9 ±6.4 24.1-44.2 30.0 ±4.8 23.9-38.6 
Resting Heart Rate (b.min -1) 79.0 ±7.9 68-90 73.8 ±8.0** 62-84 
Resting SBP (mm Hg)  136.3 ±10.2 120-150 126.3 ±7.4** 115-140 
Resting DBP (mm Hg) 94.4 ±13.4 82-125 91.1 ±13.4 80-122 
Waist Circumference (cm) 101.5 ±17.2 78.0-136.7 100.4 ±15.2 77.8-130.5 
Hip Circumference (cm)  107.0 ±10.5 93.0-126.8 105.8 ±13.7 89.0-136.0 
SBP: Systolic Blood Pressure    DBP   Diastolic Blood Pressure * Derived from the sum of triceps, biceps, suprailiac 
and subscapular skinfold thickness **p<0.05, versus pre-trial, students t test  
 
Table 4.3: Physical Characteristics of Control Group (CG) (n=2) and Active Control (AC) (n=1) 
 CG AC 
 
Characteristics 









Mass (kg)  86.3 ±28.8 65.9-106.6 85.6 ±30.0 64.4-106.8 94.5 91.3 
Stature (cm) 165 ±0.01 164-165 165 ±0.01 164-165 1.75 1.75 
% Body Fat 35.2 ±12.5 26.4-44.0 35.0 ±11.4 26.9-43.0 27.5 26 
BMI (kg.m-2) 31.9 ±10.9 24.2-39.7 31.7 ±11.4 23.7-39.7 30.78 29.83 
Heart Rate(b/min -1) 82 ±2.8 80-84 80.5 ±5.0 77-84 68 62 
SBP (mm Hg)  136 ±5.7 132-140 140 ±0.0 140-140 132 130 
DBP (mm Hg) 94 ±19.8 80-108 95 ±14.1 85-105 92 90 
Waist Circumference (cm) 92 ±9.90 85-99 92.75 ±12.4 84.0-101.5 96 93 
Hip Circumference (cm) 111.6 ±21.9 96.1-127 111.5 ± 24.8 94-129 106 104 
BMI: Body Mass Index   SBP: Systolic Blood Pressure    DBP   Diastolic Blood Pressure  
* Derived from the sum of triceps, biceps, suprailiac and subscapular skinfold thickness  
 
As is evident in Table 4.3, there were no clinically significant changes in the physical characteristics of 







4.3 Hematological Characteristics 
 
The results of the hematological analysis performed on the venous blood samples taken at the baseline 
and post-trial assessments are presented in Table 4.4 below and a graphical representation of BDNF 
concentration changes is given in Figure 4.1. 
  
Table 4.4: Hematological Analyses of Blood of the Active Group (AG) (n=8), Control Group 
(CG) (n=2) and Active Control (AC) (n=1). 
Characteristics Mean (± SD) 
PRE 
Mean (± SD) 
POST 
p Value 
Active Group (n=8)    
HbA1C (%) 7.45 (±1.34) 7.66 (±1.58) 0.32 
BDNF (pg.ml-1) 13.65 (±3.34) 16.37 (±4.46) 0.12 
Adiponectin (μg.ml-1) 1.37 (±1.32) 1.24 (±1.26) 0.74 
 
Sedentary Control Group (n=2) 
   
HbA1C (%) 6.75 (±1.20) 6.65 (±1.20) - 
BDNF (pg.ml-1) 20.38 (±3.38) 18.93 (±1.92) - 
Adiponectin (μg.ml-1) 1.73 (±2.30) 1.61 (±1.57) - 
 
Active Control Group (n=1) 
  - 
HbA1C (%) 7.00 7.70 - 
BDNF (pg.ml-1) 10.40 6.73 - 
Adiponectin (μg.ml-1) 
 
2.15 2.38 - 
p>0.05, versus pre-trial, Students t test; - no comparative statistical analysis due to small sample size 
Of the 8 participants in the AG, 7 (87.5%) had a pre-trial HbA1c reading of higher than 6.5% with the 
values ranging from 5.3 to 9.3%.  As shown in Table 4.4 and Figure 4.1, the mean ( SD) HbA1c 
measured in the active participants prior to exercise intervention was 7.45% ( 1.34) and increased to 
7.66% ( 1.58) post exercise intervention, which was not statistically significant (p> 0.05).   
 
In terms of the change in mean ( SD) of plasma BDNF concentrations (Table 4.4 and Figure 4.1) the 
individual plasma BDNF concentrations increased in 4 of the 8 active subjects (50%).  However the 
change in mean ( SD) as a result of the 8-week interval exercise intervention, did not reach statistical 
significance (p=0.116) and ranged from -6.06 to 3.92 pg.ml-1.   
 
There was no statistical change in the AG for plasma adiponectin concentrations (p=0.74) which ranged 
from 0.10-3.20 µg.ml-1.  As there were only two participants in the CG, statistical significance of pre-post 
changes was not determined (Table 4.4 and Figure 4.1).  The same applied to AC in whom HbA1c change 

































































































Figure 4.1: Mean ± SD HbA1c (%) [TOP], plasma BDNF (pg.ml-1) [MIDDLE] and adiponectin 
(μg.ml-1) [BOTTOM] concentrations in the active group (AG), control group (CG) and active 





4.4 Diabetic Foot Assessment 
 
Pedal pulses (i.e. Dorsalis Pedis Pulse, Posterior Tibial Pulse) were present in all participants (n=11) and 
described as strong before and after the intervention in 91% (n=10). However one participant in the AG 
had a weaker Posterior Tibial Pulse that had been identified at the onset of the study and showed no 
change following the exercise intervention. 
 
The results of the quantitative objective assessment of sensory perception in the feet of the active 
participants are described in Table 4.5.  Although there was not a significant increase in the total value 
representing nervous function which increased from 64.05% (±33.56) to 82.61 (±12.17), statistically 
significant increases were only observed in patellar (p=0.0166) and ankle reflexes (p=0.0016) of the AG. 
As is shown in Table 4.6, improvement was also noted in the AC.    
 
Table 4.5: Diabetic Foot Assessment of Active group (AG) (n=8). Results expressed as means ( SD) 








Pressure Perception (%) 99.4±1.8 95-100 95.0±14.1 60-100 
Vibration Perception (%) 89.6±19.7 50-100 89.5±23.6 33-100 
Sharp/ Blunt Discrimination (%) 65.6±39.9 0-100 68.8±22.2 50-100 
Temperature Perception (%) 59.4±32.6 0-100 78.1±20.9 50-100 
Dull/ Light Touch (%) 93.8±11.6 75-100 100.0±0.0 100-100 
Patella Reflex (%) 28.1±36.4 0-100 71.9±36.4* 0-100 
Ankle Reflex (%) 12.5±23.1 0-50 75.0±26.7* 50-100 
Total % nerve function               64.1±33.6 12.5-99.4 82.6±12.2 0-100 






Table 4.6: Diabetic Foot Assessment of Control Group (CG) (n=2) and Active Control (AC) (n=1) 
Characteristics 
 
                  CG 





            CG 









Pressure Perception (%) 100±0.0 20-20 100±0.0 100-100 100  100 
Vibration Perception (%) 100±0.0 100-100 100±0.0 100-100 100  100 
Sharp/ Blunt Perception (%) 62.5±17.7 50-75 62.5±17.7 50-75 50  100 
Temperature Perception (%) 75±35.4 50-100 87.5±17.7 75-100 75  75 
Dull/ Light Touch (%) 100±0.0 100-100 100±0.0 100-100 100  100 
Patella Reflex (%) 50±70.7 0-100 50±70.7 0-100 25  75 
Ankle Reflex (%) 25±35.4 0-50 75±35.4 50-100 25  50 
Total % nerve function  73.2±29.3 50-100 82.1±20.2 50-100 80.4 91.3 
 
 
PART TWO:  ANIMAL WORK FOCUSING ON POSSIBLE MECHANISMS 
 
4.5 Compliance with Study Protocol 
 
Using the previously–reported cut-off of a glucose concentration >16.7mmol.l-1 (>300mg.dl-1; Islam and 
Du Toit, 2009) as criterion for the existence of diabetes, 6 of the 7 rats were classified as diabetic.  In the 
7th rat 3h FBG concentration only reached 12.3mmol.l-1.  As this animal did therefore not meet the 
requirements of a diabetic model, it was decided that it will continue with the exercise program, but will 
regarded as a Pre-Diabetic Exercise (PDBE) rat on which a case study would be done. 
 
During the 8th week of the investigation, one rat in the DBC group sustained an injury during handling 
and had to be put down.  All remaining animals (as shown in Table 4.7), completed the full 5-week 
exercise program and the full duration each exercise session.    
 
Table 4.7: Summary of animal models after inducing diabetes using FR-10 STZ induction 
GROUP 1 GROUP 2 GROUP 3 CASE STUDY 






















As shown in Figure 4.2, the weekly water intake and blood glucose was significantly higher in DBE and 
DBC groups than in the NC group (p>0.05) with that of PDBE rat lying well above the mean of NC 
group too. While the increase in body mass was significantly less in DBE group than both DBC and NC 
groups, that of the PDBE rat was less affected by the STZ injection than those in DBE and DBC groups. 
The 3hFBG was considerably lower in PDBE rat than in DBC and DBE rats with values dropping close 





   
Figure 4.2: Mean weekly water intake (ml) [TOP] and 3 hour fasting blood glucose (3hFBG) 
concentrations (mmol.l-1) [MIDDLE] and body mass (g) [BOTTOM] for Normal Control (NC), Diabetic 
Control (DBC) and Diabetic Exercise (DBE) groups and Pre-diabetic Exercise (PDBE) rat calculated 
weekly over the 10 week investigation.   Data is represented with mean ± SD per group # p<0.0001, Repeated 








The plasma fructosamine, BDNF and adiponectin concentration in the NC, DBC and DBE groups and as 
well as PDBE rat, are shown in Figure 4.3. The fructosamine was significantly higher in DBC and DBE 






Figure 4.3: Mean ± SD plasma fructosamine (mmol.l-1) [TOP], BDNF (pg.ml-1) [MIDDLE] and 
adiponectin concentrations (µg.ml-1) [BOTTOM] in the Normal Control (NC), Diabetic Control (DBC), 
Diabetic Exercise (DBE) groups and Pre-Diabetic Exercise (PDBE) rat after the 5-week exercise 
program.  Data is represented with mean ± SD per group # p<0.0001, Repeated measures ANOVA, *p<0.05 vs 



































Figure 4.4: Mean ± SD plasma insulin concentrations (μg.l-1) in the Normal Control (NC), Diabetic 
Control (DBC) and Diabetic Exercise (DBE) groups and Pre-diabetic Exercise (PDBE) rat after the 5-
week exercise program. Data is represented with mean ± SD per group # p<0.0001, Repeated measures ANOVA, 
*p<0.05 vs NC, post-hoc Bonferroni's Multiple Comparison Test.  
 
There was a significant difference in plasma insulin concentrations between the NC, DBC and DBE 
groups (p= 0.0347) (Figure 4.4). The DBE and DBC groups had the lowest insulin concentrations, the 
pre-diabetic rat presented with an insulin concentration higher than in NC group.  The mean concentration 
of both DBC and DBE were significantly lower (p= 0.0276) than that of NC group.  
 
Mean ± SD plasma adiponectin concentrations μg.l-1) revealed a significant difference between the groups 




While the exercise program in the human clinical study showed a significant decrease in mean heart rate 
and blood pressure (p> 0.05), the only parameters that were significantly affected by the exercise training 
were the ankle and knee reflexes (p> 0.05).  
 
In the rodent work, the PDBE rat presented with a considerably higher post-exercise-training blood 
insulin and lower blood glucose concentrations than in the DBC and DBE groups. Circulating adiponectin 
















PART ONE:  CLINICAL TRIAL ON HUMAN PARTICIPANTS 
 
5.1 General Observations and Challenges 
 
Although T2DM is prevalent in today’s western society and a total of 79 potential participants, who 
possessed DPN and met all other inclusion criteria, were approached and invited to participate in this 
study, the small eventual sample size must be acknowledged as a major short coming of this pilot work.   
Several factors may have accounted for the difficulty in obtaining a large enrollment for the study and 
compliance from the participants.  
 
Firstly, as detailed on page 20 and by the ADA (2012), the presence of symptoms of DPN implies that the 
diabetic condition has persisted for some time and become a chronic condition.  Although participants 
were required to continue with their routinely prescribed medication for the control of the blood glucose 
concentration , the  HbA1c levels which exceeded 6.5%  in 86% of AG (n=7), do indicate that either the 
dosage of the medication was not sufficient to maintain normal concentrations in the AG, or a lack of 
adherence to the prescription. Furthermore, the physiological response to chronically elevated blood 
glucose concentrations resulting in DPN (Figure 2.3) would suggest that pharmacological glucose 
regulation has been inadequate over a long period leading to probable pancreatic cell dysfunction (ADA, 
2012) which may have involved both failure of the β cells to produce sufficient insulin to regulate glucose 
metabolism as well as possible further glucose production due to α cell dysfunction and excess production 
of glucagon (ADA, 2012).  Although manageable, this condition is widely accepted as being irreversible 
and often results in a negative state of mind and a set of behavioral habits becoming ingrained in patients 
possessing symptoms of DPN (ADA, 2005; Desphande et al., 2008). This may therefore have contributed 
to lack of interest in participating in the study in so large a percentage of the patients originally 
approached (n=79).  
 
The study was also restricted to participants who had been referred to a podiatry practice due to 
complaints of symptoms of DPN and were in the age range of 34-47 years.  A commitment to a regular 
exercise program did not appear to be a priority to the patients at this stage of their lives as this age group 
are generally at the peak of their careers.  Financial demands and family commitments are also commonly 
a first priority in this age group and despite the availability of exercise facilities, flexible training times 





by the researcher when attempting to persuade the diabetic patients at a podiatry practice to take part in 
this clinical trial.  
 
T2DM is also widely accepted to develop in response to a sedentary lifestyle combined with a high 
carbohydrate and fat diet, high levels of stress and pressurized time-lines (Diabetes.co.uk, 2014).  The 
dietary intake was not specifically controlled, but in order to ensure that diet did not have a confounding 
effect, each trialist was expected to undertake not to change his/her diet and to keep this consistent 
throughout the eight weeks. Hence this study investigated whether exercise alone would have a beneficial 
effect on glucose regulation and symptoms of DPN.  As the dietary intakes were not carefully monitored 
by means of regular dietary record keeping, this aspect must however be acknowledged as a further 
potential limitation of the study. 
 
A variance in stress levels could also not be controlled in the human participants other than via a 
questionnaire in which participants described that in terms of lifestyle, sleep pattern and stress levels, in 
which no significant change occurred in both groups.   Although caffeine intake did not appear to be 
excessive in any of these participants, the quantity of beer some consumed was a concern due to its high 
carbohydrate and alcohol content (Diabetes.co.uk, 2014).  From the information obtained from pre- and 
post-questionnaires and interaction with the participants during the course of the training programme, it 
can however be assumed that this potentially negative variable did not change over the 8-week period of 
the study.  
 
A strength of the program was that the eventual AG of 8 compliant patients were given individual 
attention, their training routines were carefully monitored, and they received continual feedback and 
encouragement to stay in the program and not change their lifestyle and/or dietary intake while on the 
programme. Although the exercise programme may have been more effective in eliciting greater 
physiological changes had the exercise intervention lasted longer than 8 weeks and permitted greater 
increases in training intensity as the cardiovascular endurance of the participants in AG improved, this 
was unfortunately not possible within the scope of this pilot work for a Masters by course work.  
 
Another limitation of this study was the failure to obtain a matched CG of similar size to the AG. Due to 
lifestyle and stress related factors specified above, which were also applicable to the CG, it was very 
difficult to obtain compliance from non-active participants without additional financial support for the 
study which would have enabled the remuneration of participants for their time and effort.  Hence, a 
statistical comparison between pre-post data within the CG and between the control and AG was not 
possible. Data are reported as mean ± SD, but no comparative inter-group statistical analyses were 
undertaken.  This study will therefore be classified as an uncontrolled study which only examined the pre-






5.2 The participants 
 
The active and control participants were selected strictly according to the inclusion criteria in order to 
minimise confounding factors and to maintain internal validity.  These included the age-range, 
pharmacological control of blood glucose concentration, absence of infection or the diagnosis with 
conditions which have been shown to result in sensory peripheral neuropathy, but are not related to 
diabetes (e. g. heavy metal poisoning, vitamin B12 deficiency, renal disease, chronic inflammatory 
demyelinating neuropathy, inherited neuropathies or vasculitis).  All participants possessing chronic 
lifestyle associated disorders or co-morbidities of diabetes, provided evidence of receiving appropriate 
medication and did not change the dosage shortly before and during the duration of the study.  
 
5.3 The results of the exercise intervention 
 
Although the exercise intervention included relatively high intensity interval type training and does 
appear to have been of optimal duration or intensity, there was a statistically significant improvement in 
pre-trial resting HR and BP (p<0.05). Mass, waist and hip circumference did, however, not change 
significantly within the AG (p>0.05), but only showed improvement in the AC.   In addition, mean body 
fat percentage (33.4± 4.6) and BMI of the active participants (30.0 ± 4.8) which was well above the 
healthy range  (WHO, 2000) in both women and men failed to drop significantly (p>0.05) in both active 
and control participants. The likely explanation for this is that it has been shown that weight loss is the 
result of combined dietary and exercise interventions. As Macfarlan and Thomas (2009) conclude, 
“although it is clear that an appropriate exercise regimen produces a clinically significant benefits in 
weight loss when used in conjunction with caloric restriction, the dominant contributor is typically likely 
to be dietary intake (80% of the weight loss), with enhanced physical activity contributing to the 
remainder (20%).”  
 
Most importantly, the exercise intervention which consisted primarily of interval training, resulted in a 
significant drop in mean resting heart rate (p=0.012) from 79.6 to 73.8 bpm in the AG, although still 
elevated above the accepted normal readings of 60-70bpm.   As reading above 80bpm may indicate a 
weak myocardium and therefore exercise would be indicated, none of the participants presented with 
tachycardia (a resting heart rate above 100bpm) which should be investigated for underlying conditions 
(Thomas and Draper, 2011).     
 
The mean resting systolic blood pressure measured in the active participants prior to the exercise 
intervention also showed a significant mean reduction post exercise intervention (p=0. 043).   No change 





All participants were therefore referred back to their medical practitioners with detailed feedback after the 
trial to facilitate the making of adjustments to their prescribed medication, if needed, after the trial.   
 
5.4 Hematological Characteristics 
 
The mean HbA1c measured in the active participants (AG) prior to exercise intervention (7.25 ± 1. 34 %) 
did not change (p>0. 05) remaining above the normal HbA1c range of non-diabetic individuals (3.9 - 
5.5%) and above the threshold used to be diagnosed with diabetes (>6. 5%).  Only 3 of the 8 participants 
(37.5%) and one of the participants in the CG adhered to the recommendation of ADA (2005) that once 
diagnosed and treated for diabetes, the HbA1c reading must remain close 6.5%. Interestingly, in 62.5% 
(n=5) of the participants, an HbA1c reading close to 7% was recorded. This coincides with a blood 
glucose value greater than 8.6 mmol.l-1 and has been associated with damage to organs due to 
hyperglycaemia (Diabetes Outreach Country Health, 2011),  
 
Although, as explained by Huang and Czech (2007) and Earnest et al., (2008), an acute bout of endurance 
exercise training has been shown to provide a strong stimulus for mitochondrial biogenesis that increases 
GLUT4 concentration, thus facilitating muscle glucose transport (Huang and Czech, 2007; Earnest et al., 
2008) and it is proposed that GLUT4 protein expression increases with regular endurance exercise and 
that impairment in GLUT4 transport/ translocation may be the cause of insulin resistance (Earnest, 2008), 
the current 8-week exercise intervention alone appeared not to be intense and long enough to support a 
beneficial effect on glucose regulation.    
 
Furthermore, the current study also failed to support the contention that a graded endurance exercise 
programme and improved endurance training status attenuates the glucagon and epinephrine release at 
rest and a given exercise load  (Galbo et al., 1975), hence reducing HbA1c in the long term. 
The possible explanation for the failure of glucose regulation, as represented by HbA1c which represents 
the mean blood glucose concentration over a 3month period, to change following the 8-week exercise 
intervention, is two-fold: 
 
Firstly it is most probably related to the chronic nature of the diabetes and the permanent pancreatic 
dysfunction that is most likely to have occurred in these participants who had already developed DPN.  
Unfortunately a limitation of this work is that it was not possible to obtain fasting blood samples from the 
participants which would have been required to measure plasma insulin concentration and hence 
permitted calculation of HOMAIR (Bonora et al., 2002).  The glucose-insulin ratio was however 
addressed in the follow-up rodent work completed in part two of this thesis.    
 
Although Raz et al. (1994) emphasize that exercise should be an integral part of management in T2DM 





max (Kelley and Kelley, 2007). As the members of the AG had a mean (±SD) BMI of 30.9 ±6.45 with 
50% falling into the obese category and entered the programme with a prior history of sedentary lifestyle, 
the intensity of the exercise program was relatively low.  Hence it can be concluded that in the 
convenience sample of T2DM patients who presented with DPN, the exercise training intervention of 8-
weeks in duration was not sufficiently intense to result in an improvement in HbA1c and hence glucose 
control. Although it does therefore not confirm the findings of Cauza et al. (2005), Sigal et al. (2007), Ng 
et al. (2010) and Laaksonen et al. (2005), it does support the findings of Knowler et al. (2002), Pan et al. 
(1997), Mc Auley et al. (2002) and Umpierre et al. (2011) that exercise is only beneficial if combined 
with dietary recommendations.   
 
A second possible reason for no change in HbA1c values in the current study is aligned with the findings 
of Burns et al., (2007). He explains that there are certain DM susceptibility genotypes that might 
predispose individuals to respond or not to respond to exercise.  Unfortunately it was beyond the scope of 
this study to include an investigation of the genetic profile of the AG.  
 
Although the failure of the plasma BDNF concentrations which rose in only 50% (n=4) of the AG, to 
increase significantly (p= 0.12; Table 4.4) following the 8- week intervention, may in part be attributed to 
the low statistical power of the study and high standard deviations within the group, it does also appear to 
support previous findings of Schulz et al. (2004a), Levinger et al. (2008) and Goekint et al. (2010).  The 
data therefore fails to support the findings of Cuppinin (2007) who reported an exercise-induced elevation 
blood BDNF concentrations attributed to the additional release of BDNF by contracting skeletal muscle.  
As this result was possibly also due to the inability to implement a sufficiently intense exercise 
programme, further research is needed to investigate the possible effects of chronic exercise on BDNF 
concentrations when the exercise training intervention is longer than 8-weeks in duration and a higher 
training intensity can be achieved as the participants improve their level of fitness. 
 
HbA1c as mentioned, did not decrease in the AG. As HbA1c has been shown to be inversely proportional 
to plasma BDNF (Nakawaga et al., 2000), this supports the observation that plasma BDNF did not rise 
significantly (p>0.05). As previously mentioned, greater intensity, frequency and duration of the exercise 
program may have however produced a greater enhancement of these BDNF concentrations which may, 
in turn, have positively affected HbA1c in the AC.  
 
Plasma adiponectin concentrations also demonstrated no significant change in AG.   These findings 
correlate with no change in the HbA1c concentrations as these parameters have also been shown to be 
inversely proportional to one another (Schulz et al., 2004b).  The findings of this study thus confirm the 
findings of the two non-randomized controlled trials which showed no change in circulating adiponectin 






5.5 Diabetic Foot Assessment 
 
The most important finding focuses on one of the primary objectives of the study, which was to determine 
the effects of an interval exercise program on DPN in T2DM patients, was that sensory peripheral 
neuropathy measured in the active participants showed significant improvement in knee and ankle 
reflexes as compared to that of prior to the 8-week exercise intervention.  Interestingly, the two members 
of the CG demonstrated further loss of mean nerve function over the 8-week period.    
 
This improvement in knee and ankle reflexes however may not be attributed to glucose control as these 
parameters showed no change and may lend support to the hypothesis of  Paulsen et al.(2012) for 
improvement in reflex strength following exercise training.  These researchers propose that exercise 
results in the increase in epinephrine concentrations which interacts with the β2-adrenergic receptors, 
resulting in a sympathetic response.   This response causes an increase in contractile activity and 
metabolic enzyme activity with resultant increased reflex strength (Paulsen et al., 2012).  Further work is, 
however, required to confirm this theory and to confirm no link between glucose control and these 
reflexes and the findings of this study which was only based on the data obtained from a small sample 
(n=8).  
 
The findings of this pilot work did furthermore not confirm those of Gurney (2011) who demonstrated 
quantifiable changes in sensory function as a result of a low-impact balance and strength training 
intervention in diabetic participants with DPN and a significant improvement in sensory threshold at three 
of the four tested foot sites as well as for the average foot sensory threshold.   
 
 
PART TWO:  ANIMAL WORK FOCUSING ON POSSIBLE MECHANISMS 
 
Due to the limitations of the pilot work conducted on a small sample of human subjects and the practical 
restrictions of working with humans including their unavailability to provide fasting blood samples and 
the difficulties associated with controlling life-style variables such as food, alcohol and caffeine intake, 
stress levels, environmental factors and general activity when not participating in the exercise 
programme, it was decided to look more deeply into the responses of diabetic rodents to a 5-week 






5.6 Confirmation of Diabetes 
  
Using the cut-off of a 3hFBG concentration > 16. 7mmol. l-1 (>300mg. dl-1) as criterion for the existence 
of diabetes (Islam and Du Toit, 2009), 6 of the 7 rats were classified as diabetic.  In the 7th rat 3h FBG 
concentration only reached a 3hFBG concentration of 12.3 mmol.l-1.   As this animal did therefore not 
meet the requirements of a diabetic model, it was decided to continue with the exercise program with this 
rat, but to classify it as a Pre-Diabetic Exercised (PDBE) rat on which a case study would be conducted 
comparing its responses to the exercise plus fructose withdrawal regime, to those of the rats in the DBC 
and DBE groups in which pancreatic damage had been induced.   
 
5.7 Effects of the Intervention 
 
In both DBC and DBE groups as well as the PDBE rat, polydipsia, polyphagia and mass loss was 
confirmed, supporting previous findings (ADA, 2005; diabetes.co.uk, 2014).  The slower rate of increase 
in the mean body mass (g) as the rats matured in DBC and DBE groups (p<0. 001),  is a well-documented 
consequence of the untreated diabetic state, which was, in this case, induced by a combination of dietary 
fructose intake and the STZ injection.   It is well known that insulin is an anabolic hormone which 
stimulates glycogen and triglyceride synthesis (Guyton and Hall, 2011). If insufficient, the diffusion of 
glucose into the muscle cells and its metabolism to create ATP is slowed down.  When this occurs, the 
body starts burning fat and muscle for energy, causing a reduction in overall body mass (NINDS, 2013).  
 
Of great importance in terms of the findings of this study, are the blood fructosamine concentrations. As 
described in the literature review, it is a glycosylated protein formed when carbohydrate and protein, 
primarily albumin, bond non-enzymatically and can be used as an assessment for glycaemic control and 
blood glucose concentrations over a longer period (half-life about 17 days in the circulation).   
Fructosamine therefore represents a shorter term glycaemic control than HbA1c (Rigg, 2012), hence it is 
more appropriate for use in studies on rodents.   Confirming the trend seen in the 3hFBG concentrations 
during the exercise intervention, the mean ± SD plasma fructosamine levels (mmol. l-1) were significantly 
higher (p=0.0015) in DBC and DBE groups than in the NC group and well correlated with final 3hFBG 
concentrations (r=0.7070), confirming the findings of  Ladan et al. (2011).  
 
In terms of metabolic regulation of glucose homeostasis, the mean ± SD plasma BDNF concentrations 
(pg. ml-1) in the DBE group which were significantly higher (p= 0. 0201) than in the DBC and NC groups 
and support the findings of a study by Cuppinin (2007) who published one of the first papers reporting an 
exercise-induced elevation in blood BDNF concentrations attributed to the additional release of BDNF by 





regulation (Nakawaga et al., 2000), this was only apparent in the PDBE rat and did not occur in the DBE 
group in which pancreatic dysfunction had been induced by injection of STZ. 
 
Most interesting was the significant difference between the mean ± SD plasma insulin concentrations 
post-trial (pmol. l-1) between the three groups (p=0.0347) and the fact that the highest plasma insulin 
concentration was recorded in the PDBE rat, with  DBC and DBE groups presenting with the lower 
plasma insulin concentrations than in the NC group.  Pinhas-Hamiel and Zeitler (2013) explain that the 
development of diabetes from normal glucose tolerance is a continuous process.   The first stage is 
characterized by insulin resistance accompanied by a compensatory increase in insulin secretion, as seen 
in the PDBE group.   Those with both IFG and IGT have insulin resistance, but the site of their 
predominant insulin resistance differs.   Those with IFG have predominantly hepatic insulin resistance, 
whereas those with IGT have predominantly muscle insulin resistance.   In the second stage, β cells fail to 
compensate for increased insulin resistance and hyperglycaemia develops, progressing from prediabetes 
to diabetes as βcell failure increases, resulting in progressive loss of βcell secretion as was seen in the 
DBC group who presented with lower plasma insulin concentrations.  It must be acknowledged that the 
latter however probably results from a combination of genetic, environmental and biochemical 
determinants (Pinhas-Hamiel and Zeitler, 2013).   
 
Furthermore the difference noted between the mean ± SD plasma insulin concentrations (μg. l-1) in DBC 
and DBE groups can be explained as resulting from increased glucose uptake as exercise training 
provides a strong stimulus for mitochondrial biogenesis that increases GLUT4 concentration.  Contraction 
of the skeletal muscle stimulates the cell to translocate GLUT4 receptors to the surface, thus facilitating 
muscle glucose transport and therefore decreasing the need for insulin secretion (Earnest, 2008). In the 
PDBE rat, insulin concentration is the highest and the fact that is considerably higher than in the three 
groups, can possibly be explained as a compensatory increase in insulin secretion during the first stage in 
T2DM. 
  
Mean ± SD plasma adiponectin concentrations (μmol.l-1) revealed a significant difference between the 
groups (p=0.0111) and a positive correlation with insulin concentrations (r=0.747; p<0.05).  This 
confirms previous findings (Weyer et al., 2001) that plasma levels of adiponectin are significantly lower 








It can therefore be concluded that following the exercise programme, hypoinsulinaemia (p<0. 05) with 
elevated 3hFBG, plasma fructosamine and plasma BDNF (p>0. 05), but unchanged plasma adiponectin 
(p> 0. 05) were recorded in the DBE group (n=6), while hyperinsulinaemia was recorded in the PDBE rat 
with reduced 3hFBG and plasma fructosamine and elevated plasma adiponectin and BDNF levels.    
 
The data from this study therefore suggest that endurance exercise, together with fructose withdrawal 
from the diet, is not effective in reversing diabetic status, but may be effective in improving glycaemic 
status in the pre-diabetic stage confirming previous findings by Hwang et al. (2011).   
 
In case of PDBE rat, 3hr FBG, plasma fructosamine was less than DBE rats, plasma insulin 
concentrations was greater than NC and an increase in both plasma BDNF and adiponectin concentrations 
provides evidence of improved glycaemic control and suggests that endurance exercise is not effective in 



















CONCLUSIONS AND RECOMMENDATIONS FOR FUTURE RESEARCH 
 
From the results of these two pilot studies it can be concluded that when, as was the case of the study on 
humans, the condition is chronic and has existed for years resulting in peripheral sensory damage, 
exercise alone is unlikely to reverse the condition.  This was also confirmed in the DBE group of the 
rodent study in which pancreatic damage had been induced via injection of STZ.  
 
The possibility of the exercise programme resulting in an improvement in reflex nervous function which 
is independent of glucose control, in humans with T2DM that is accompanied by DPN, does however 
require further verification.  
 
In the rodent work it was found that in the PDE rat which presented with a higher blood insulin 
concentration, the exercise programme together with fructose withdrawal, however appeared to have a 
positive effect on glucose regulation.  This was confirmed by the elevated fructosamine, adiponectin and 
BDNF concentrations in this rat and requires confirmation in further randomised controlled studies in 
which the effect of exercise alone vs. restriction of dietary intake of CHO alone, is examined on 
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PARTICIPANT INFORMATION FORM 
 
Ms. Louise Stirk and Professor Edith Peters-Futre from the Division of Human Physiology in the School 
of Laboratory Medicine and Medical Sciences of the College of Health Sciences at the University of 
KwaZulu-Natal would like to conduct the following research project:  
 
THE EFFECTS OF AN 8-WEEK ENDURANCE EXERCISE PROGRAM ON GLUCOSE 
CONTROL AND PERIPHERAL SENSORY NEUROPATHY IN PARTICIPANTS WITH TYPE 2 
DIABETES 
 
You are being invited to consider participating in this study. 
Background to the study: 
Diabetic peripheral neuropathy (DPN) is a common complaint amongst diabetic patients and is a great 
cause for concern as it can lead to other serious complications such as pedal ulcers and possible gangrene 
and amputation (Diabetic Care, 2012).  Although there is much evidence confirming the beneficial effects 
of different exercise modalities on glucose control in the Type 2 diabetic patient, only one research report 
focusing on the benefits of exercise on DPN has been completed to date.  This reported beneficial effects 
with significant improvements in sensory function following a low-impact and strength training exercise 
intervention (Gruney, 2011).   
 
We are however not sure about what causes this improvement in nervous function and reduced pain in 
their feet after participating in an exercise program and whether endurance exercise will have the same 
effect.  It has been shown that certain brain derived factors are also released by skeletal muscle during 
endurance exercise and that these factors lower blood glucose concentration, improve insulin sensitivity 
and increase   resting energy expenditure (Nakagawa et al., 2000; Cuppinin et al., 2007; Krabbe et al., 
2007).  We therefore would like to determine whether an endurance exercise program results in a 
lessening of the signs and symptoms of DPN 
i. an improvement in glucose control 
ii. raised factors released by the brain and contracting skeletal muscle which have been 
associated with glucose control 
 
Who is eligible to participate in this study? 
Type 2 diabetic participants between 34 and 48 years old who  
 have diagnosed  DPN 
 no other chronic illness 
 exercise less than an hour a week  
 are willing to participate in all aspects of the trial, which includes regular exercise intervention, completing 
questionnaires, provision of small  blood samples before and after the intervention and clinical tests 
(neurological testing) 





and do not…  
 possess any ailment or chronic illness that will impede participation in the 8-week exercise program (e.g. 
pedal ulcer, Cardiac Autonomic Neuropathy, rheumatoid arthritis) 
 make regular or chronic use of medication for improved peripheral sensory neuropathy 
 
What will be expected from volunteers in this study?  
  
You will be asked to: 
1. present yourself for baseline clinical measurements and assessments prior to the onset of program  
2. attend all the scheduled spinning classes i.e. 3 times a week for 8 weeks 
3. maintain your usual diet and training status throughout the study  
4. provide a small (4ml) venous blood sample before and after the exercise intervention 
5. present yourself for a post-intervention clinical measurements and assessments after completion of the 
8-week program    
 
Outline of tests 
 
On 2 occasions (i.e. pre- and post-assessment) you will be required to present yourselves to the Exercise 
Physiology Laboratory, Department of Human Physiology, School of Laboratory Medicine and Medical 
Sciences, Westville Campus, UKZN. 
 
During the pre-assessment, you are to complete a general baseline questionnaire to assess your; i) general 
health status, ii) lifestyle and iii) physical activity and whether you are able to exercise without causing 
exercise-induced complications that are prevalent in diabetic patients. Your peripheral sensory 
neuropathy status will be assessed by a qualified podiatrist (Louise Stirk B. Tech Pod (SA)) in addition to 
the details provided already after an assessment of your vital signs by a physician. This will include a 
questionnaire to determine the degree of sensory peripheral neuropathy symptoms experienced. The signs 
of sensory peripheral neuropathy will be quantitatively assessed using a 10g monofilament, 128Hz tuning 
fork, Neurotip, Tip Therm, patella hammer and a piece of cotton wool. Lastly a physician will draw a 
venous blood to provide a sample for testing HbA1c and BDNF concentrations.  
 
The exercise intervention i.e. a 30 minute spinning class will be completed three times a week for 8 
weeks under the supervision of a qualified spinning instructor. This will be completed on 20 “spinning 
bikes” in an environmental controlled exercise laboratory in the PRIME Performance Fitness Centre at 
the MOSES Mabida Stadium. Participants will wear a Polar hear rate monitor with telemetric links to a 
central recorder enabling the instructor, a specialist in Exercise Physiology, to ensure that the heart rate of 
participants is kept within a range of  60-80% of their previously calculated maximum heart rate. At all 
times, a medical doctor, specialized in Sports Medicine, will be on standby to manage any adverse event 
or possible complications that may arise.  
 
The post-assessment will be concluded after the exercise intervention has been completed. The level of 
peripheral sensory neuropathy will be determined as done in the pre-assessment. Another venous blood 
sample will be drawn by the physician to test HbA1c and BDNF. The samples will be handled and tested 
as previously mentioned for the pre-assessment.  
 
How can you benefit from participation in this study?  
 
Following the study, you will be given the results of each of the clinical and laboratory tests. 
  
By participating you will establish whether the effects of an 8-week endurance exercise program 
improves peripheral sensory neuropathy in type 2 diabetics and the possible association with HbA1c 






Will you be exposed to adverse effects of the study? 
 
A minimal risk factor is involved in any physical test and all necessary precautions will be taken to ensure 
safe conditions.  
 
There is a very slight risk of complications from venipuncture (taking of blood), mainly infection at the 
site of puncture or inflammation (swelling) of the vein used.  
 
In the unlikely event of a complication occurring, Dr. Craig Roberts will be present at all of the 
assessments and taking of the blood samples. He will ensure that procedures are performed according to 
the same standards that you would experience in a hospital environment.  
 
Medical insurance is available in case of the event of an adverse effect. 
 
Can you withdraw from the study?  
 
As your participation is entirely voluntary, you may withdraw from the study at any time without penalty.  
 
Will your individual results remain confidential?  
 
Yes.  The records identifying the participants will be kept confidential and, to the extent permitted by the 
applicable laws and/or regulations, will not be made publicly available. The study is for degree purposes, 




Any out-of-pocket expenses which you may incur as a result of your participation in this study (e.g. 
traveling expenses) will also be reimbursed by the research team. 




Should you have any queries or wish to obtain further details regarding this study, please do not hesitate 
to contact us. 
Ms. Louise Stirk – 082 839 9203             
Prof. Edith Peters-Futre - (031) 260 4237 (W); 0737597974 
Contact details of REC administrator and chair – for reporting of complaints / problems. 
BIOMEDICAL RESEARCH ETHICS ADMINISTRATION  
University of KwaZulu-Natal  
Research Office, Westville Campus  
Govan Mbeki Building  
Private Bag X 54001, Durban, 4000  
KwaZulu-Natal, SOUTH AFRICA  
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THE EFFECTS OF AN 8-WEEK ENDURANCE EXERCISE PROGRAM ON GLUCOSE 
CONTROL AND PERIPHERAL SENSORY NEUROPATHY TYPE 2 DIABETIC 
PARTICIPANTS 
 
                                                         PARTICIPANT CONSENT FORM 
 
I, ……………………………………………………………………….. hereby agree to participate in a 
research study to be performed by Ms. Louise Stirk and Professor Edith Peters-Futre in the Division of 
Human Physiology in the College of Health Sciences of the University of KwaZulu-Natal. I have been 
informed about the study by the principal investigator, Ms. Louise Stirk and understand my participation 
is at my own risk. 
 
I understand that the basic procedures to be carried out are to include:  
1. Completion of a 30-mininute spinning class three times a week for 8 weeks. 
2. Completion of a brief medical and general health questionnaire before the exercise intervention 
and provision of 2ml blood samples before and after the exercise intervention. 
 
The details of these procedures have been explained to me in full. I am aware that a certain level of 
discomfort may occur when the blood is taken and that this procedure may be accompanied by certain 
medical risks including infection and inflammation of the vein.    
 
I understand that this study will form part of the Masters degree of Ms. Louise Stirk and that the results 
may be published.  
 
I understand that participation is entirely voluntary and that I may withdraw from the study at any time. 
 
I may contact the principal investigator of the project, Ms. Louise Stirk at 082 839 9203 at any time if I 




_________________                        ______________ 







____________________                  __________________ 
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THE EFFECTS OF AN 8-WEEK ENDURANCE EXERCISE PROGRAM ON GLUCOSE 
CONTROL AND PERIPHERAL SENSORY NEUROPATHY IN TYPE 2 DIABETIC 
PARTICIPANTS 
 
                                             BASELINE QUESTIONNAIRE 
 
1. Participant code…………………….   2.  Date of Birth……………………. 
 
 
PART A:  GENERAL HEALTH STATUS 
1. Are you currently in good health? (i.e. No illness within the last 3 months) 
Yes □     No □    If no, please specify 
…………………………………………………………………………………………………………
………………………………………………………………………….. 
2. Do you suffer from any of the following? Please tick. 
Heavy metal poisoning       yes □     no □ 
Vitamin B12 deficiency       yes □     no □ 
Renal disease        yes □     no □ 
Chronic inflammatory demyelinating neuropathy    yes □     no □ 
Inherited neuropathies       yes □     no □ 
Vasculitis         yes □     no □ 
 
3. Do you suffer from any chronic medical conditions that have been diagnosed more than 3 months 
ago? E.g. high blood pressure, high cholesterol.   




4. Please list any medication that you are currently taking. This includes over the counter 





With regard to your feet,  
  YES NO 
1 Has a doctor diagnosed you with neuropathy?   
2. Do you have burning pain?   
3. Are they sensitive to the touch?   
4. Do you have a prickling/ pins and needles feeling in your feet?   
5. Can you tell from hot and cold water with your feet?   
6. Have you had an ulcer on your feet?   
7. Are your feet numb?   
8. Are your symptoms worse at night?   
9. Are you able to sense your feet when walking?   





Adapted from: Michigan Neuropathy Screening Instrument (Lawrence A et al. Screening for Diabetic 
Neuropathy. Diabetic Microvascular Complications Today. 17-19. 2004) 
 
PART B: LIFESTYLE 
 
Sleep Pattern 
Number of hours per night?...............................................................…. 
Insomnia:  Yes □     No □ 
 
Smoking 
Do you presently smoke?  Yes □     No □ 





Do you presently consume alcohol?  Yes □     No □ 
If yes, please specify number of drinks per week 
Beer (340ml)……………………. 
Wine (250 ml)…………………… 
Spirits (tots)…………………….. 
 
Caffeine Intake  
Mark the appropriate intake with an X 
Coffee: None      1-3 cups per day      >3 cups per day 
Tea:   None         1-3 cups per day       >3 cups per day  
 
Stress levels 





How would you describe your regular dietary intake? Please indicate with an X 
Prudent: Low carbohydrate, transfat & saturated fat, red meat content & high fruit & 
vegetable content 
 
High carbohydrate, low fat  
High fat, low carbohydrates     
High protein, high fat  
 
Are you cautious about your intake of refined sugars and candies? Yes □     No □ 
Are you a vegetarian?   
If so, please specify whether vegan, lacto-vegetarian, lacto-ovo-vegetarian  
If partially vegetarian, please explain briefly…………………………………. 
Do you supplement with Vitamin B12?                       Yes □     No □ 











   
YES 
    
NO 
1.  Do you feel pain in your chest at rest, during your daily activities of 
living or when you do physical activity? 
  
2.  Do you lose balance because of dizziness or have you lost 
consciousness in the last 12 months? Please answer NO if your 
dizziness was associated with over breathing (including during 
vigorous exercise) 
  
3.  Do you have a bone or joint problem that could be made worse by 
becoming more physically active? Please answer NO if you had a 
joint problem in the past, but it does not limit your current ability to 
be physically active. For example knee, ankle, shoulder or other   
  
4.  Has your doctor ever said that you should only do medically 
supervised physical activity? 
  
5.  How many hours in the day are you physically active?  
6.  Of those hours that you are physically active, how many are 
structured exercise? 
 
7.  What structured exercise do you do?  
Adapted from: The Physical Activity Readiness Questionnaire for Everyone. (PAR-Q+ CSEP approved. 
2011) 
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THE EFFECTS OF AN 8-WEEK ENDURANCE EXERCISE PROGRAM ON GLUCOSE 
CONTROL AND PERIPHERAL SENSORY NEUROPATHY IN TYPE 2 DIABETIC 
PARTICIPANTS 
 
                                             POST TRIAL QUESTIONNAIRE 
 
2. Participant code…………………….   2.  Date of Birth……………………. 
 
 
PART A:  GENERAL HEALTH STATUS: 
5. Have you been in good health? (i.e. No illness within the last 8 weeks) 








7. With regard to your feet,  
  YES NO Not 
applicable 
Comment 
1. Has the burning pain 
improved? 
    
2. Has sensitivity to touch 
improved? 
    
3. Has the prickling/ pins& 
needles feeling in your feet 
improved? 
    
4. Has your perception of hot 
and cold water on your feet 
improved? 
    
5. Has the numbness in your feet 
improved? 
    
6. Are the symptoms at night 
better? 
    
7. Are you able to sense your 
feet better when walking? 
    
8. Has the leg pain when 
walking improve? 
    
9. Any additional comments re sensory changes in your feet? 
 
Adapted from: Michigan Neuropathy Screening Instrument (Lawrence A et al. Screening for Diabetic 







PART B: LIFESTYLE 
Sleep Pattern: 
Number of hours per night?...............................................................…. 
Have you suffered from insomnia during the 8 weeks?  Yes □     No □ 
 
Alcohol intake: 
Did you consume alcohol?  Yes □     No □ 
If yes, please specify number of drinks per week 
Beer (340ml)……………………. 
Wine (250 ml)…………………… 
Spirits (tots)…………………….. 
 
Caffeine Intake:  
Mark the appropriate intake with an X 
Coffee: None      1-3 cups per day      >3 cups per day 
Tea:   None         1-3 cups per day       >3 cups per day  
 
Stress levels: 
How would you rate your overall stress level during the 8 weeks of the trial? (1- coping well; 10- not 




How would you describe your regular dietary intake during the 8 weeks?  
Please indicate with an X 
Prudent: Low refined carbohydrate, transfat & saturated fat, red meat content 
& high fruit & vegetable content 
 
High carbohydrate; Low fat  
High fat; Low carbohydrates     
High protein, high fat  
Were you cautious about your intake of refined sugars and candies? Yes □     No □ 
Did you supplement with Vitamin B12?  Yes □     No □ 




PART C: PHYSICAL ACTIVITY QUESTIONAIRE  
  
 
   
YES 
    
NO 
8.  Do you feel pain in your chest at rest, during your daily activities of 
living or when you do physical activity? 
  
9.  Do you lose balance because of dizziness or have you lost 
consciousness in the last 12 months? Please answer NO if your 
dizziness was associated with over breathing (including during 
vigorous exercise) 
  
10.  Do you have a bone or joint problem that could be made worse by 
becoming more physically active? Please answer NO if you had a 
joint problem in the past, but it does not limit your current ability to 
be physically active. For example knee, ankle, shoulder or other   
  
11.  Has your doctor ever said that you should only do medically 
supervised physical activity? 
  
 
12.  How many hours in the day were you physically active?  
13.  Of those hours that you are physically active, how many were 






14.  What structured exercise did you do in addition to the spinning  
programme? 
 




PART D: FINAL GENERAL QUESTIONS 
 




How did you feel about completing the exercise program? …………………………………….. 
Did you enjoy it?........................................................... 
 
How was the intensity?  too easy             appropriate            challenging             very challenging  
 
Describe any negative or positive reactions to the regular exercise which you would like the researchers 








     
